

# **WHO methods and data sources for global burden of disease estimates 2000-2021**

---

*Department of Data and Analytics  
Division of Data, Analytics and Delivery for Impact  
WHO, Geneva*

*May 2024*



**Global Health Estimates Technical Paper WHO/ DDI/DNA/GHE/2024.3**

## Acknowledgments

This Technical Report was updated by Bochen Cao , with inputs and assistance from Jessica Ho. Estimates of deaths and YLL by cause for years 2000-2021 were primarily prepared by Bochen Cao, Gretchen Stevens, Jessica Ho and Doris Ma Fat, of the Monitoring, Forecasting and Inequality Unit in the WHO Department of Data Analytics, in the Division of Data, Analytics and Delivery for Impact of the World Health Organization (WHO), Geneva, drawing heavily on advice and inputs from other WHO Departments, collaborating United Nations (UN) Agencies, and WHO expert advisory groups and academic collaborators.

The YLD estimates draw heavily from the work of the Institute of Health Metrics and Evaluation (IHME) at the University of Washington, and their many collaborators in the Global Burden of Disease 2021 Study. Other inputs to these estimates result from collaborations with Interagency Groups, expert advisory groups and academic groups. The most important of these include the Interagency Group on Child Mortality Estimation (UN-IGME), the UN Population Division, the Child and Adolescent Causes of Death Estimation (CA CODE) project, the Maternal Mortality Expert and Interagency Group (MMEIG), the International Agency for Research on Cancer, and UNAIDS.

Estimates and analysis are available at:

<https://www.who.int/data/global-health-estimates>

For further information about the estimates and methods, please contact [healthstat@who.int](mailto:healthstat@who.int)

### *Recent papers in this series*

1. WHO methods and data sources for life tables 1990-2021 (Global Health Estimates Technical Paper WHO/DDI/DNA/GHE/2024.1)
2. WHO methods and data sources for country-level causes of death 2000-2021(Global Health Estimates Technical Paper WHO/DDI/DNA/GHE/2024.2)



## Table of Contents

Acknowledgments.....	i
Table of Contents.....	ii
1 Introduction .....	3
1.1 Background .....	3
1.2 Cause of death categories.....	4
1.3 Other analysis categories.....	4
1.4 What is new in this update for years 2000-2021.....	4
2 The disability-adjusted life year.....	6
2.1 Simplified DALY .....	7
2.2 Standard expected years of life lost for calculation of YLLs .....	7
2.3 Age weighting and time discounting .....	8
2.4 Prevalence versus incidence YLDs .....	9
2.5 Comorbidity adjustment.....	11
3 Disability weights for calculation of YLDs .....	12
3.1 Evolution of methods for estimation of disability weights.....	12
3.2 Disability weights revisions for GBD 2016 and GHE 2016 .....	12
4 YLD estimates for diseases and injuries.....	14
4.2 Uncertainty in YLD estimates.....	15
5.5 Conclusions .....	19
References.....	20
Annex Table A GHE cause categories and ICD-10 codes.....	24
Annex Table B Health states and lay descriptions used in the GBD study.....	30
Annex Table C Health state weights used in WHO Global Health Estimates .....	42

# 1 Introduction

## 1.1 Background

A consistent and comparative description of the burden of diseases and injuries, and the risk factors that cause them, is an important input to health decision-making and planning processes. Information that is available on mortality and health in populations in all regions of the world is fragmentary and sometimes inconsistent. Thus, a framework for integrating, validating, analyzing and disseminating such information is useful to assess the comparative importance of diseases and injuries in causing premature death, loss of health, and disability in different populations.

The World Bank commissioned the first Global Burden of Disease (GBD) study for its World Development Report 1993 (World Bank, 1993) and the study was carried out in a collaboration between the Harvard School of Public Health and the World Health Organization. This first GBD study quantified the health effects of more than 100 diseases and injuries for eight regions of the world in 1990 (Murray & Lopez, 1996). It generated comprehensive and internally consistent estimates of mortality and morbidity by age, sex and region. The study also introduced a new metric – the disability-adjusted life year (DALY) – as a single measure to quantify the burden of diseases, injuries and risk factors (Murray, 1996). The DALY is based on years of life lost from premature death and years of life lived in less than full health; it is described in more detail in Section 2.

Drawing on extensive databases and information provided by Member States, WHO produced annually updated GBD estimates for years 2000 to 2002. These were published in the WHO's annual *World Health Reports*, followed by two stand-alone reports for the year 2004 (WHO, 2008; WHO, 2009a). The new estimates reflected an overhaul of methods for mortality estimation in the setting of sparse data, improved approaches for dealing with problems in cause of death certification, new cause of death modelling strategies, and use of improved tools for ensuring internal consistency of mortality and epidemiological estimates (Mathers, Lopez & Murray, 2006; WHO, 2008). The GBD results for the year 2001 also provided a framework for cost-effectiveness and priority setting analyses carried out for the Disease Control Priorities Project (DCPP), a joint project of the World Bank, WHO, and the National Institutes of Health, funded by the Bill & Melinda Gates Foundation (Jamison et al, 2006a). The GBD results were documented in detail, with information on data sources and methods, and analyses of uncertainty and sensitivity, in a book published as part of the DCPP (Lopez et al, 2006). The GBD cause list was expanded to 136 causes (giving a total of 160 cause categories, including group totals). The WHO GBD updates incrementally revised and updated estimates of incidence, prevalence and years of healthy life lost due to disability (YLDs) for non-fatal health outcomes. By the time of the GBD 2004 study, 97 of the 136 causes had been updated, including all causes of public health importance or with significant YLD contribution to DALYs.

In 2007, the Bill & Melinda Gates Foundation provided funding for a new GBD 2010 study, led by the Institute for Health Metrics and Evaluation at the University of Washington, with key collaborating institutions including WHO, Harvard University, Johns Hopkins University, and the University of Queensland. This study also drew on wider epidemiological expertise through a network of about 40 expert working groups, comprising hundreds of disease and injury subject-matter experts including many working in WHO programs. The GBD 2010 study developed new methods for assessing causes of death and for synthesizing epidemiological data to produce estimates of incidence and prevalence of conditions for 21 regions of the world.

To meet WHO's need for comprehensive global health statistics, which brings together WHO and interagency estimates for all-cause mortality and priority diseases and injuries, as well as drawing on the

work of academic collaborators, including IHME, updated Global Health Estimates (GHE) for mortality, causes of death, and disease burden, are being progressively released. This commenced with the release in mid-2013 of updated regional-level estimates of deaths by cause, age and sex for years 2000-2011 (WHO, 2013), followed by country-specific estimates for the years 2000-2012 (WHO, 2014), later updated to years 2000-2015 (WHO, 2016), years 2000-2016 (WHO, 2018), and years 2000-2019 (WHO, 2020).

To meet the need for DALY estimates consistent with the GHE for cause-specific mortality, WHO also released regional- and country-level estimates of DALYs by cause, age and sex for years 2000-2019 at <https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates> (WHO, 2020).

WHO has now released updated estimates of deaths and DALYs by cause, age, and sex for years 2000-2021 as part of its update of Global Health Estimates 2021 (GHE2021). This technical paper documents the data sources and methods used for preparation of the burden of disease estimates for years 2000-2021.

## 1.2 Cause of death categories

In addition to the cause of death categories used in the previous WHO burden of disease estimates, we added two more categories, namely COVID-19 and other pandemic related mortality (OPRM), to account for the emerging disease burden caused by the COVID-19 pandemic. To reconcile deaths associated with COVID-19 excess mortality and cause-specific pandemic-related deaths, OPRM was introduced in GBD2021 to capture all deaths due to the pandemic which were not specifically caused by COVID-19 or the indirect COVID causes. It is equal to the difference between excess mortality and the sum of COVID-19 specific deaths, measles, lower respiratory infection (LRI), and pertussis.

Annex Table A lists the cause categories and their definitions in terms of the International Classification of Diseases, Tenth Revision (ICD-10). The cause categories are grouped into three broad cause groups: Group I (communicable, maternal, perinatal and nutritional conditions), Group II (noncommunicable diseases); and Group III (injuries). The cause list has a hierarchical structure so that different levels of aggregation are included. At each cause level, the list provides a set of mutually exclusive and collectively exhaustive categories.

## 1.3 Other analysis categories

Estimates are made for 183 WHO Member States with populations greater than 90,000 in 2021. The 11 Member States excluded are: Andorra, Cook Islands, Dominica, Marshall Islands, Monaco, Nauru, Niue, Palau, Saint Kitts and Nevis, San Marino, and Tuvalu. Additionally, estimates are made for the three largest populations in non-Member State territories or areas: Puerto Rico; Taiwan, China, occupied Palestinian territory, including east Jerusalem. These are not released at country level, but are included in the relevant regional and global totals.

Estimates are disaggregated by sex and age for the following age groups: neonatal (<28 days), 1-59 months, 5-14, 15-29, 30-49, 50-69, 70 years and older.

YLL, YLD and DALY estimates are available on the WHO website for countries and for a number of regional groupings as defined in Annex B to Technical Paper 2024.3 (WHO 2024).

## 1.4 What is new in this update for years 2000-2021

These WHO GHE provide a comprehensive and comparable set of DALY estimates from year 2000 onwards, consistent with and incorporating estimates for the WHO all-cause mortality and cause of

deaths in the same GHE update, as well as GBD 2021 analyses for YLDs, with some revisions and methodological differences as summarized below:

- A simpler form of DALY, used by the GBD 2010 study (Murray et al, 2012b), has been adopted. This form is easier to explain and use (see Section 2). Age-weighting and time discounting are dropped, and the YLDs are calculated from prevalence estimates rather than incidence estimates. YLDs are also adjusted for independent comorbidity.
- The standard life table used for calculation of years of life lost for a death at a given age is based on the projected frontier life expectancy for 2050, with a life expectancy at birth of 90 years (see Section 2.2)
- The years of life lost from mortality (YLLs) are calculated using WHO estimates of deaths by region, cause, age and sex for years 2000-2021 being released in the same GHE update(WHO 2024).
- Estimates of YLD draw on the GBD 2021 analyses (GBD 2021 Diseases and Injuries Collaborators, 2024), with selected revisions to disability weights and prevalence estimates as noted below.
- Limited revisions have been made to disability weights for infertility, intellectual disability, vision loss, hearing loss, dementia, drug use disorders, skin diseases and low back pain as previously documented (WHO 2013b).

Because these estimates draw on new data and on the results of the GBD 2021 study, and there have been substantial revisions to methods for many causes, these estimates for the years 2000-2021 are not directly comparable with previous WHO estimates of DALYs.

## 2 The disability-adjusted life year

The DALY is a summary measure which combines time lost through premature death and time lived in states of less than optimal health, loosely referred to as “disability”. The DALY is a generalization of the well-known Potential Years of Life Lost measure (PYLLs) to include lost good health. One DALY can be thought of as one lost year of ‘healthy’ life and the measured disease burden is the gap between a population’s health status and that of a normative reference population. DALYs for a specific cause are calculated as the sum of the YLLs from that cause and the YLDs for people living in states of less than good health resulting from the specific cause:

$$DALY(c,s,a,t) = YLL(c,s,a,t) + YLD(c,s,a,t) \quad \text{for given cause } c, \text{ age } a, \text{ sex } s \text{ and year } t$$

The YLLs for a cause are essentially calculated as the number of cause-specific deaths multiplied by a loss function specifying the years lost for deaths as a function of the age at which death occurs. The basic formula for YLLs is the following for a given cause  $c$ , age  $a$ , sex  $s$  and year  $t$ :

$$YLL(c,s,a,t) = N(c,s,a,t) \times L(s,a)$$

where:

$N(c,s,a,t)$  is the number of deaths due to the cause  $c$  for the given age  $a$  and sex  $s$  in year  $t$

$L(s,a)$  is a standard loss function specifying years of life lost for a death at age  $a$  for sex  $s$

The GBD 1990 study chose not to use an arbitrary age cut-off such as 70 years for the loss function used in the calculation of YLLs, but rather specified the loss function in terms of the life expectancies at various ages in standard life tables with life expectancy at birth fixed at 82.5 years for females and 80.0 years for males. These represented approximately the highest observed life expectancies for females in the mid-1990s, together with an assumed biologically-determined minimum male-female difference.

The GBD 1990 and subsequent WHO updates used an incidence perspective for the calculation of YLDs. To estimate YLDs for a particular cause in a particular time period, the number of incident cases in that period is multiplied by the average duration of the disease and a weight factor that reflects the severity of the disease on a scale from 0 (perfect health) to 1 (dead):

$$YLD(c,s,a,t) = I(c,s,a,t) \times DW(c,s,a) \times L(c,s,a,t)$$

where:

$I(c,s,a,t)$  = number of incident cases for cause  $c$ , age  $a$  and sex  $s$

$DW(c,s,a)$  = disability weight for cause  $c$ , age  $a$  and sex  $s$

$L(c,s,a,t)$  = average duration of the case until remission or death (years)

The ‘valuation’ of time lived in non-fatal health states formalises and quantifies the loss of health for different states of health as *disability weights*.

In the standard DALYs reported by the original GBD study and in subsequent WHO updates, calculations of YLDs and YLLs used an additional 3% time discounting and non-uniform age weights that give less weight to years lost at young and older ages (Murray, 1996). Using discounting and age weights, a death in infancy corresponds to 33 DALYs, and deaths at ages 5–20 years to around 36 DALYs.

## **2.1 Simplified DALY**

Following the publication of the GBD 1990, there has been extensive debate on all the key value choices incorporated into the DALY – the years lost on death, the disability weights, age weights and time discounting (Anand & Hanson, 1997; Williams, 1999; Murray et al, 2002; Lyttkens, 2003; Arnesen & Kapiriri, 2004; Bognar, 2008). Additionally, the incidence-based perspective required substantial modelling of incidence and average durations for many diseases where the available data mainly related to prevalence. The GBD 2010 study held a consultation in July 2011 with 21 philosophers, ethicists, and economists to advise on the value choices that should be incorporated into the DALY summary measure used for the GBD 2010. An earlier expert consultation in 2008 addressed the conceptual, ethical and measurement issues in undertaking a comprehensive revision of disability weights (Salomon, 2008).

Following these consultations, the GBD 2010 and subsequent studies chose to simplify the calculation of DALYs (Murray et al, 2012b; Murray et al, 2012c) as follows:

- Use of a new normative standard life table for the loss function used to compute YLLs;
- Calculation of YLDs simply as the prevalence of each sequela multiplied by the relevant disability weight
- Adjustment for comorbidity in the calculation of YLDs
- No discounting for time or unequal age weights

Following informal consultations with relevant WHO programs, collaborators and expert advisory groups in late 2012, WHO decided to adopt the simplified calculation methods for DALYs as described in more detail in the following sections, albeit with an updated loss function for the computation of YLLs.

## **2.2 Standard expected years of life lost for calculation of YLLs**

The standard reference life table for the GBD 1990 was based on the highest observed life expectancy at the time, Japanese females with a life expectancy at birth close to 82.5 years. Based on the observed male-female gap in life expectancy in the best-off communities within high-income countries, the standard reference life expectancy was set to 80.0 years at birth for males. The standard reference life table is intended to represent the potential maximum life span of an individual in good health at a given age. For the GBD 2010 study, it was decided to use the same reference standard for males and females and to use a life table based on the lowest observed death rate for each age group in countries of more than 5 million in population. The new GBD 2010 reference life table has a life expectancy at birth of 86.0 years for males and females.

However, some of the experts consulted by WHO argued that it was not appropriate to set the normative loss of years of life in terms of currently observed death rates, since even for the lowest observed death rates there are a proportion of deaths which are preventable or avertable. In fact, Japanese females have already exceeded the GBD 2010 reference life expectancy at birth, with a life expectancy at birth in 2013 of 87.1 years. Since the loss function is intended to represent the maximum life span of an individual in good health, who is not exposed to avoidable health risks, or severe injuries, and receives appropriate health services, we chose to base this on the frontier national life expectancy derived from the lowest projected age-specific mortality rates for the year 2050 by the World Population Prospects 2024 (UN Population Division, 2024).

The highest projected life expectancies for the year 2050 are projected to be achieved with a life expectancy at birth of 92.7 years. While this may still not represent the ultimate achievable human life spans, it does represent a set of life spans which are thought likely to be achieved by a substantial

number of people who are alive today (Kontis et al 2017). Table 2.1 summarizes the loss function used for the calculation of YLLs in the WHO GHE.

*Table 2.1 Standard loss functions used in Global Burden of Disease studies and for WHO Global Health Estimates*

Age range	GBD 1990 age-weighted, discounted		GBD 1990 no age-weights or discounting		GBD 2010	WHO GHE
	Male	Female	Male	Female	Persons	Persons
Neonatal	33.27	33.38	79.94	82.43	86.01	92.65
Postneonatal	34.22	34.34	78.85	81.36	85.68	92.21
1-4	35.17	35.29	77.77	80.28	83.63	89.74
5-9	37.22	37.36	72.89	75.47	78.76	85.25
10-14	37.31	37.47	67.91	70.51	73.79	80.26
15-19	36.02	36.22	62.93	65.55	68.83	75.27
20-24	33.84	34.08	57.95	60.63	63.88	70.28
25-29	31.11	31.39	52.99	55.72	58.94	65.31
30-34	28.08	28.40	48.04	50.83	54.00	60.34
35-39	24.91	25.30	43.10	45.96	49.09	55.38
40-44	21.74	22.19	38.20	41.13	44.23	50.43
45-49	18.63	19.16	33.38	36.36	39.43	45.51
50-54	15.65	16.26	28.66	31.68	34.72	40.61
55-59	12.82	13.52	24.07	27.10	30.10	35.74
60-64	10.19	10.96	19.65	22.64	25.55	30.92
65-69	7.80	8.60	15.54	18.32	21.12	26.21
70-74	5.71	6.45	11.87	14.24	16.78	21.62
75-79	4.00	4.59	8.81	10.59	12.85	17.19
80-84	2.68	3.09	6.34	7.56	9.34	13.08
85+	1.37	1.23	3.82	3.59	5.05	7.28

## 2.3 Age weighting and time discounting

The GBD 1990 study and subsequent WHO updates published DALYs computed with a 3% discount rate for future lost years of healthy life and an alternative set with a 0% discount rate. The arguments for discounting future health were couched mainly in terms of avoiding various decision-making paradoxes when future costs of health interventions are discounted (Murray & Acharya, 2002). Critics have argued that there is no intrinsic reason to value a year of health as less important simply because it is in the future (Tsuchiya, 2002) and the experts consulted for the GBD 2010 study also advised against discounting, particularly in the context where the DALY has been more explicitly defined as quantifying loss of health, rather than the social value of loss of health. This also avoids the inconsistency in the original DALY method, where the start time for discounting future stream of YLDs was the year of incidence, whereas that for YLLs was the year of death.

The original GBD 1990 study and subsequent WHO updates also incorporated age-weighting in the standard DALYs used in most publications and analyses. The standard age weights gave less weight to years of healthy life lost at young ages and older ages (Murray, 1996). With the clearer conceptualization of DALYs as purely a measure of population health loss rather than broader aspects of social welfare, it is difficult to justify the inclusion of age weights, and the GBD 2010 study dropped them

(Murray et al, 2012b; Jamison et al, 2006b) has argued for an alternate form of age-weighting, for incorporating stillbirths and deaths around the time of birth into the DALY. This modifies the loss function for years of life lost for a death at a given age (or gestational age) to reflect “acquired life potential”, by which the fetus or infant only gradually acquires the full life potential reflected in the standard loss function. Murray et al (2012c) have argued that such considerations should be reflected in social priorities rather than in the basic health measure itself.

Following informal consultations in 2012, WHO decided to adopt the same approach as GBD 2010 in computing DALYs with a time discount rate of 0% and no age-weighting. This change results in a substantial increase in the absolute number of DALYs lost and a relative increase in the share of DALYs at younger and older ages (WHO 2018).

## 2.4 Prevalence versus incidence YLDs

DALYs were calculated in the GBD 1990 and subsequent WHO updates using an incidence perspective for YLDs. Incident YLDs were computed as the stream of future health loss associated with disease sequelae incident in the reference year. This was done to ensure consistency with the YLL calculation, which takes an inherently incidence perspective, although prevalence-based YLDs were also calculated for other purposes, such as the calculation of period healthy life expectancy.

The incidence-based YLD approach has three major disadvantages. First, it will not reflect the current prevalent burden of disabling sequelae for a condition for which incidence has been substantially reduced. Secondly, the YLD calculation requires estimates of both incidence and average duration of disease sequelae, whereas for many health conditions it is primarily prevalence data that are collected. Third, in an incidence perspective, all YLDs for a condition are assigned to the age-groups at which the condition is incident, whereas the policy-maker is often more interested in the ages at which the loss of health is experienced. Finally, incorporation of comorbidity is more straightforward in a prevalence approach than an incidence approach.

Given these advantages of a prevalence approach, both the GBD 2010 and WHO have decided to switch to a prevalence-based approach to calculation of YLDs. The major impact of this is to shift the age distribution of YLDs significantly (Figure 2.1). Thus for example YLDs for congenital hearing loss will be spread relatively evenly across all age groups in the prevalence perspective, whereas they will all fall at age 0 in an incidence perspective.




Figure 2.1 Age distribution of global YLD for the year 2004 (WHO 2008). Classic YLD are incidence-based with age-weighting and 3% time discounting; incidence and prevalence YLD are not age-weighted or discounted.

## 2.5 Comorbidity adjustment

Earlier versions of the GBD reported YLDs calculated separately for individual disease and injury causes without adjustment for comorbidity. These were added across causes to obtain total all-cause YLDs. Some limited adjustments for comorbidity were incorporated into subsequent WHO updates. For example, prevalence estimates for depression, substance use disorders and anxiety disorders were adjusted to take into account quite substantial levels of comorbidity between these conditions, so that double or triple counting did not occur for DALYs for these individuals. More comprehensive adjustments for comorbidity across all conditions was required for the calculation of healthy life expectancy. The first WHO estimates for HALE adjusted for YLD comorbidity assuming independence of conditions (the probability of having two comorbid conditions is the product of the individual probabilities of the two conditions). Later, a method for taking dependent comorbidity into account was applied (Mathers, Iburg & Begg, 2006).

Because many people have more than one disease or injury, particularly at older ages, addition of YLDs across causes may result in overestimation of the total loss of health. This is particularly important at the oldest ages, where summed YLDs may approach or exceed 100% of person-years. Following expert consultations, the GBD 2010 and subsequent revisions implemented adjustments for independent comorbidity so that summed YLDs across causes reflect the sum of the overall lost health at the individual. Individuals with the same functional health loss are then treated as like regardless of whether that functional health loss came from one or several contributing conditions.

The GBD 2010 study estimated comorbidities using the assumption of independence within age-sex groups:

$$p_{1+2} = p_1 + p_2 - p_1 \times p_2 = 1 - (1 - p_1) \times (1 - p_2) \quad (1)$$

where  $p_{1+2}$  is the prevalence of the two comorbid diseases 1 and 2,  $p_1$  is the prevalence of disease 1 and  $p_2$  the prevalence of disease 2.

It tested this assumption using UW Medical Expenditure Panel Survey data and concluded that the error in magnitude of YLDs from using the independence assumption was minimal. The combined disability weight for individuals with multiple conditions is estimated assuming a multiplicative model as follows:

$$DW_{1+2} = 1 - (1 - DW_1) \times (1 - DW_2)$$

Since prevalence YLDs are calculated for each individual cause as:

$$YLD_i = DW_i \times p_i \quad (2)$$

the two preceding equations can be combined into a single calculation resulting in:

$$YLD_{1+2} = 1 - (1 - YLD_1) \times (1 - YLD_2) \quad (3)$$

Using the GBD 2004 estimates for non-age-weighted, undiscounted YLDs as an example, adjustment for independent comorbidity reduces global all-age YLDs by 6% and YLDs for ages 60 and over by 11%.

## **3 Disability weights for calculation of YLDs**

### **3.1 Evolution of methods for estimation of disability weights**

In order to use time as a common currency for non-fatal health states and for years of life lost due to mortality, we must define, measure and numerically value time lived in non-fatal health states. While death is not difficult to define, non-fatal health states are. They involve multiple domains of health which relate to different functions, capacities or aspects of living. In the GBD studies, the numerical valuation of time lived in non-fatal health states is through the so-called disability weights, which quantify loss of functioning on a scale where 0 represents perfect health and 1 represents a state equivalent to death. Depending on how these weights are derived and what they are attempting to quantify, they are variously referred to as disability weights, quality-adjusted life year (QALY) weights, health state valuations, utilities or health state preferences.

In the earliest version of the GBD 1990 study, the burden of disease was defined as loss of welfare/subjective well-being/quality of life (World Bank, 1993). Murray (1996) subsequently argued that the health state values should reflect societal judgements of the value of averting different diseases rather than individual judgments of the disutility of the diseases. As a result, the 1996 version of the GBD 1990 used two forms of the person-trade-off (PTO) method to assess social preferences for health states and asked small groups of health professionals in weighting exercises to make a composite judgment on the severity distribution of the condition and the social preference for time spent in each severity level (Murray, 1996). Dutch researchers subsequently used the same methods to estimate disability weights for the Netherlands (Stouthard et al, 1997; Stouthard, Essink-Bot & Bonsel, 2000). The version of PTO used by the GBD study was criticized as unethical by a number of commentators (Arnesen & Nord, 1999) and rejected for the same reason by project participants in a European multi-country study following on from the Dutch study (Schwarzinger et al, 2003). Other criticism of the GBD 1990 approach to valuation of health states related to the use of judgements from health professionals rather than the general population, or those with the conditions, and to the use of universal weights rather than weights that varied with social and cultural environment.

During the period 2000-2008 in which WHO was carrying out updates of the GBD using the original disability weights, with some revisions and additions (Mathers, Lopez & Murray, 2006), the conceptual thinking behind the GBD made explicit the aspiration to quantify loss of health, rather than the social value of the loss of health, or of wellbeing (Murray & Acharya, 2002; Salomon et al, 2003). In this conceptualization, health state valuations formalize the intuitive notions that health levels lie on a continuum and that we may characterize an individual as being more or less healthy than another at a particular moment in time. Health state valuations quantify departures from perfect health, i.e., the reductions in health associated with particular health states. Thus in the GBD terminology, the term *disability* is used broadly to refer to departures from optimal health in any of the important domains of health and disability weights should reflect the general population judgments about the ‘healthfulness’ of defined states, not any judgments of quality of life or the worth of persons or the social undesirability or stigma of health states.

### **3.2 Disability weights revisions for GBD 2016 and GHE 2016**

The GBD 2010 study undertook a comprehensive re-estimation of disability weights through a large-scale empirical investigation with a major emphasis on surveying respondents from the general

population, in which judgments about health losses associated with many causes of disease and injury were elicited through a new standardized approach. The GBD 2010 study estimated disability weights for 220 health states using a method involving discrete choice comparisons of “health” for pairs of health states described using lay descriptions consisting of a brief summary of the health state of an average or modal case in 30 words or less (see Salomon et al 2012 for details of lay descriptions, survey and statistical methods). Paired comparisons data were collected from 13,902 individuals in household surveys in five countries, supplemented by an open-access web-based survey of 16,328 people. This study represents the most extensive empirical effort to date to measure disability weights. Salomon et al (2012) also concluded that they found strong evidence of highly consistent results across the samples from different cultural environments.

In the GBD 2010 disability weights paper, Salomon et al (2012a). note that the new disability weights are much higher for some health states (such as heroin addiction, acute low back pain) and much lower for a larger number of health states, including infertility (0.01, previously 0.18), moderate to profound hearing loss (0.02-0.03, previously 0.12-0.33), blindness (0.20, previously 0.60) and intellectual disability (for severe intellectual disability 0.126, previously 0.82). Experts from the GBD Vision Loss Expert Group noted the surprisingly low disability weights for severe vision disorders and suggested that the cause was inadequate descriptions of the consequences of vision disorders (Taylor et al, 2013).

Nord (2013) argued that these problems result from the explicit framing the discrete choice comparisons of sequelae in terms of “who is healthier”. Even if blindness is significantly limits functioning, blind people are – in everyday language – not ‘sick’ or ‘ill’. Given this, many respondents may not have thought of blind people as being in poor health. Other states with which this semantic and conceptual point may have led to unreasonably low weights are for example ‘deafness’ ( $dw = 0.03$ ), ‘amputations of legs and two artificial legs’ (0.05) and ‘paralysed below the waist, moves about with a wheelchair’ (0.05). Alternatively, it is also possible that the “lay descriptions of these health states” were inadequate in some way.

WHO’s earlier estimates of DALYs for years 2000-2011 made adjustments were made to a number of the GBD 2010 disability weights for permanent long-term disabilities as described in a previous Technical Paper (WHO 2013b). IHME also recognized that there were problems with these weights, and a number of others with implausible face validity, and carried out an additional valuation exercise using revised health state descriptions (Salomon et al 2015).

Salomon et al (2015) carried out new web-based surveys in 2013 of 30,660 respondents in four European countries (Hungary, Italy, the Netherlands, and Sweden). These surveys included 183 health states; of which 30 were revised descriptions and 18 were for new health states. Health state descriptions were revised for most of the health states revised by WHO for the previous GHE2013 YLD estimates. In particular, descriptions were revised for spinal cord injury, hearing loss, and cognitive impairments. Valuations were also obtained for new health state descriptions relating to five mild health states for alcohol and drug dependence outcomes, which are now also used in the GHE 2016.

Annex Table B lists the health states and health state descriptions used in the GBD 2015 study (Salomon et al 2015, GBD 2015 Disease and Injury Incidence and Prevalence Collaborators 2016). Annex Table C tabulates the various revisions of GBD disability weights for 234 health states and lists the weights used for the current GHE 2021 and GBD 2021 estimates.

## 4 YLD estimates for diseases and injuries

For most disease and injury causes, we have drawn on GBD 2021 estimates by country for the years 2000-2021 (GBD 2021 Diseases and Injuries Collaborators, 2024). The GBD 2021 study computed YLD as the prevalence of a sequela multiplied by the disability weight for that sequela without age weighting or discounting. The YLDs arising from a disease or injury are the sum of the YLDs for each of the sequelae associated with that disease.

For most sequelae, the GBD 2021 study used a Bayesian meta-regression method, DisMod-MR 2.1, designed to address key limitations in descriptive epidemiological data, including missing data, inconsistency, and large methodological variation between data sources. For some disorders, natural history models, back calculation from mortality rates, or other methods were used. YLDs by cause at age, sex, country, and year levels were adjusted for comorbidity with simulation methods.

For selected impairments, WHO and other collaborators have estimated the overall prevalence of the impairment (WHO 2013b). These “envelope” prevalences constrained the estimates for sequelae related to that impairment to sum to estimates of the overall impairment prevalence. For example, nine disorders have blindness as a sequela. The prevalence of all blindness sequelae was constrained to sum to blindness prevalence.

The WHO GHE draws on the GBD 2021 analyses for YLDs with some caveats. Selected disability weights are revised as described in Section 3 above. Other revisions for prevalence estimates, cause distributions and severity distributions were carried out for vision loss, hearing loss, intellectual disability, infertility, anaemia, back and neck pain, migraine, alcohol problem use, and skin diseases. These are documented in the previous Technical Paper (WHO 2013b).

In 2007, WHO established the Foodborne Disease Burden Epidemiology Reference Group (FERG) to estimate global and regional burdens of foodborne disease. Included among the parasitic foodborne diseases analysed were cysticercosis, echinococcosis, and food-borne trematodosis. In 2015, the FERG published regional and global estimates of deaths and DALYs for these diseases for the year 2010 (WHO 2015, Torgerson et al 2015). The GBD2021 time series estimates of YLD for these three diseases were scaled to match the underlying FERG estimates of deaths for 14 WHO sub-regions in 2010.

## 4.2 Uncertainty in YLD estimates

The GBD 2021 study estimated 95% uncertainty ranges for YLD estimates. Global uncertainty ranges for each cause category are summarized in the following Table, in terms of average relative uncertainty (all ages, both sexes) calculated as  $0.5 * (\text{upper bound} - \text{lower bound}) / \text{median value}$ .

*Table 4.1 Average global relative uncertainty (%) for YLD by cause. Source: GBD 2021.*

Cause code	Cause name	Av. uncertainty (±%)	Cause code	Cause name	Av. uncertainty (±%)
0	All Causes	30.6	820	Mental disorders	47.9
10	Group I	66.7	830	Depression	52.7
20	Infectious	65.5	831	Major depression	51.6
30	TB	69.1	832	Dysthymia	58.8
40	STDs	75.8	840	Bipolar disorder	55.4
50	Syphilis	62.2	850	Schizophrenia	49.4
60	Chlamydia	84.5	860	Alcohol abuse	59.5
70	Gonorrhoea	119.0	870	Drug abuse	70.7
80	Trichomoniasis	109.0	871	Opioid abuse	66.5
85	Genital herpes	83.7	872	Cocaine abuse	74.3
90	Other STDs	83.9	873	Amphetamine abuse	76.1
100	HIV/AIDS	73.0	874	Cannabis abuse	78.4
110	Diarrhoeal	46.2	875	Other drug abuse	77.8
120	Childhood-cluster	79.2	880	Anxiety disorders	50.2
130	Pertussis	57.7	890	Eating disorders	68.0
140	Diphtheria	121.6	900	Autism	39.4
150	Measles	89.9	910	Child behavioural	99.7
160	Tetanus	98.4	911	ADD	99.7
170	Meningitis	42.1	912	Conduct disorder	67.9
180	Encephalitis	36.7	920	ID	103.4
185	Hepatitis	83.5	930	Other mental	47.9
186	Acute hepatitis A	101.4	940	Neurological	92.8
190	Acute hepatitis B	83.7	950	Dementias	51.2
200	Acute hepatitis C	90.3	960	Parkinson disease	66.4
205	Acute hepatitis E	76.6	970	Epilepsy	91.7
210	Parasitic	86.8	980	Multiple sclerosis	53.4
220	Malaria	58.2	990	Migraine	104.3
230	Trypanosomiasis	79.4	1000	Other headache	178.2
240	Chagas disease	89.6	1010	Other neurological	69.9
250	Schistosomiasis	110.8	1020	Sense organ	54.8
260	Leishmaniasis	81.4	1030	Glaucoma	56.4
270	Lymphatic filariasis	52.9	1040	Cataracts	52.0
280	Onchocerciasis	67.1	1050	Refractive errors	74.8

Table 4.1 (continued) Average global relative uncertainty (%) for YLD by cause. Source: GBD 2021.

Cause code	Cause name	Av. uncertainty (±%)	Cause code	Cause name	Av. uncertainty (±%)
285	Cysticercosis	98.6	1060	Macular degen	57.6
295	Echinococcosis	80.0	1070	Other vision loss	61.8
300	Dengue	224.7	1080	Other hearing loss	47.8
310	Trachoma	80.7	1090	Other sense	68.9
315	Yellow fever	178.2	1100	CVD	48.8
320	Rabies	132.4	1110	RHD	54.7
330	Worms	77.3	1120	HHD	61.9
340	Ascariasis	87.3	1130	IHD	51.8
350	Trichuriasis	77.9	1140	Stroke	33.6
360	Hookworm disease	72.8	1141	Ischameic stroke	33.6
362	Trematodes	98.9	1142	Haem stroke	33.6
365	Leprosy	64.0	1150	Inflammatory HD	65.6
370	Other infectious	87.7	1160	Other circulatory	67.5
380	Resp infections	59.5	1170	Chronic resp	43.1
390	LRI	55.9	1180	COPD	37.5
395	COVID-19	111.7	1190	Asthma	48.6
400	URI	56.7	1200	Other resp	48.8
410	Otitis media	66.8	1210	Digestive diseases	63.1
420	Maternal	90.2	1220	Peptic ulcer disease	66.6
490	Neonata	50.3	1230	Cirrhosis	66.6
500	Preterm	39.3	1231	Cirrhosis hep B	77.9
510	Birth asphyxia	68.3	1232	Cirrhosis heps C	76.6
520	Neonatal sepsis	80.4	1233	Cirrhosis alcohol	77.9
530	Other neonatal	36.6	1234	Other cirrhosis	68.4
540	Nutritional	96.1	1240	Appendicitis	65.4
550	PEM	149.4	1241	Gastritis	69.0
560	Iodine deficiency	75.6	1242	Intestinal obstruction	59.2
570	Vit A deficiency	81.4	1244	Inflam. bowel	51.4
580	ID anaemia	99.2	1246	Gallbladder disease	58.5
590	Other nutritional	151.4	1248	Pancreatitis	76.5
600	Group II	55.6	1250	Other digestive	66.3
610	Cancers	65.1	1260	GU diseases	59.3
620	Oral cancers	58.9	1270	Kidney diseases	59.4
621	Lip and oral cavity	57.2	1271	Acute glom.	70.6
622	Nasopharynx	57.5	1272	CKD diabetes	109.1
623	Other pharynx	55.7	1273	Other CKD	58.5
630	Oesophagus ca	54.2	1280	Prostatic hyperplasia	63.6
640	Stomach cancer	54.0	1290	Urolithiasis	70.7
650	Colorectal cancers	53.6	1300	Other urinary	70.5



Table 4.1 (continued) Average global relative uncertainty (%) for YLD by cause. Source: GBD 2021.

Cause code	Cause name	Av. uncertainty (%)	Cause code	Cause name	Av. uncertainty (%)
660	Liver cancer	73.3	1310	Infertility	148.1
661	Liver cancer hep B	73.1	1320	Gynecological	46.8
662	Liver cancer hep C	84.0	1330	Skin diseases Musculoskeletal diseases	60.6
663	Liver cancer alc	81.9	1340	Rheumatoid arthritis	54.2
664	Other liver cancer	79.5	1350	Osteoarthritis	58.8
670	Pancreas cancer	51.7	1360	Gout	78.9
680	Lung cancers	57.1	1370	Back and neck pain	70.8
690	Skin cancers	69.0	1380	Other musc.	49.5
691	Melanoma	68.5	1390	Congenital	75.9
692	NMSC	76.5	1400	Neural tube defects	59.2
700	Breast cancer	60.0	1410	CL/CP	40.5
710	Cervix cancer	62.7	1420	Uterus cancer	69.4
720	Ovary cancer	64.8	1430	Down syndrome	47.0
730	Prostate cancer	70.8	1440	Congenital heart	68.8
742	Testicular cancer	71.1	1450	Other chromosomal	51.4
745	Kidney cancer	63.5	1460	Other congenital	59.2
750	Gallbladder cancer	56.2	1470	Oral conditions	62.2
751	Bladder cancer	56.5	1480	Dental caries	81.5
752	Brain cancers	55.7	1490	Periodontal disease	91.7
754	Thyroid cancer	64.4	1500	Edentulism	53.0
755	Mesothelioma	71.3	1502	Other oral disorders	46.3
760	Non-H lymphoma	58.4	1505	SIDS	NA
761	Leukaemia	69.6	1510	Group III	38.5
762	Other cancers	67.9	1520	Unintentional	38.3
763	Other neoplasms	72.6	1530	Road injury	33.1
770	Hodgkin lymphoma	59.8	1540	Poisonings	47.5
780	Non-Hodgkin lymphoma	71.8	1550	Falls	37.6
790	Other blood	66.2	1560	Fire	44.6
800	Other neoplasms	72.2	1570	Drowning	35.6
810	Diabetes mellitus	79.4	1575	Mechanical	40.1
811	Endocrine blood	51.1	1580	Disasters	40.8
812	Thalassaemias	70.9	1590	Other unintentional	40.4
813	Sickle cell	79.5	1600	Intentional	36.2
814	Other haemo	86.0	1610	Homicide	35.2
	Other endocrine	93.8	1620	Conflict	32.1
		61.1	1630	Other pandemic-related	69.7
			1700		NA

For YLD, the following guidance by cause is provided in the downloadable YLD spreadsheets for countries and regions:

-  Global average uncertainty range  $\leq$ 25<sup>th</sup> percentile (30.6% to 54.2%)
-  Global average uncertainty range >25<sup>th</sup> percentile and  $\leq$ 50<sup>th</sup> percentile (54.3% to 66.3%)
-  Global average uncertainty range >50<sup>th</sup> percentile and  $\leq$ 50<sup>th</sup> percentile (66.4% to 78.2%)
-  Global average uncertainty range >75<sup>th</sup> percentile (>78.2%)

For DALYs, colour coded guidance on uncertainty is also provided in the downloadable DALY spreadsheets for countries and regions. This colour coding by country and cause combines information on the YLL uncertainty (by country data type) and YLD uncertainty (by cause) as follows:

-  Global YLD/YLL <0.4 and multiple years of high quality death registration data are available.
- 
  - Global YLD/YLL <0.4 and multiple years of moderate quality death registration data are available; OR
  - Global YLD/YLL in range 0.4-2.4. Multiple years of high quality death registration data are available, or multiple years of moderate quality death registration data are available and average YLD uncertainty less than 54.2%; OR
  - Global YLD/YLL > 2.4 and YLD uncertainty less than 54.2%.
- 
  - Global YLD/YLL <0.4 and multiple years of low quality death registration data are available; OR
  - Global YLD/YLL in range 0.4-2.4. Multiple years of moderate quality death registration data are available, or multiple years of low quality death registration data are available and average YLD uncertainty less than 54.2%; OR
  - Global YLD/YLL > 2.4 and YLD uncertainty in range 54.3% to 66.3%.
- 
  - Global YLD/YLL <0.4 and country is low HIV country without useable death registration data; OR
  - Global YLD/YLL in range 0.4-2.4. Multiple years of low quality death registration data are available and average YLD uncertainty > 42.4%, or death registration data are not

available, country is low HIV country and average YLD uncertainty in range 66.4% to 78.2%; OR

Global YLD/YLL > 2.4 and YLD uncertainty in range 66.4% to 78.2%.

Global YLD/YLL <0.4 and country is high HIV country without useable death registration; OR

Global YLD/YLL in range 0.4-2.4, country is low HIV country without useable death registration data and average YLD uncertainty > 78.2%, or country is high HIV country without useable death registration data; OR

Global YLD/YLL > 2.4 and YLD uncertainty > 78.2%.

## 5.5 Conclusions

WHO's adoption of health estimates is affected by a number of factors, including a country consultation process for country-level health estimates, existing multi-agency and expert group collaborative mechanisms, and compliance with minimum standards around data transparency, data and methods sharing. More detailed information on quality of data sources and methods, as well as estimated uncertainty intervals, is provided in referenced sources for specific causes.

Calculated uncertainty ranges depend on the assumptions and methods used. In practice, estimating uncertainty in a consistent way across health indicators has had limited success (i.e., estimates with uncertainty typically reflect some, but not all, source of uncertainty). The type and complexity of models used for global health estimates varies widely by research/institutional group and health estimate. Where data are available and of high quality, estimates from different institutions are generally in agreement. Discrepancies are more likely to arise for countries where data are poor and for conditions where data are sparse and potentially biased. This is best addressed through improving the primary data.

Although the GHE estimates for years 2000-2021 have large uncertainty ranges for some causes and some regions, they provide useful information on broad relativities of disease burden, on the relative importance of different causes of death and disability, and on regional patterns and inequalities. The data gaps and limitations in high-mortality regions reinforces the need for caution when interpreting global comparative burden of disease assessments and the need for increased investment in population health measurement systems. The use of verbal autopsy methods in sample registration systems, demographic surveillance systems and household surveys provides some information on causes of death in populations without well-functioning death registration systems, but there remain considerable challenges in the validation and interpretation of such data.

## References

- Anand S, Hanson K (1997). Disability-adjusted life years: a critical review. *Journal of Health Economics.*16:685–702.
- Arnesen T, Nord E (1999). The value of DALY life. *British Medical Journal.*319:1423-5.
- Arnesen T, Kapiriri L (2004). Can the value choices in DALYs influence global priority-setting? *Health Policy.*70:137–149.
- Bognar G (2008). Age-weighting. *Economics and Philosophy.*24:167–189.
- GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (2016). Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet.* 2016 Oct 7; 388:1545–1602.
- GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet.* 2020;396(10258).
- GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet.* 2024 May 18;403(10440):2100-2132
- GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet.* 2024 May 18;403(10440):2133-2161
- Jamison DT, Breman JG, Measham AR, Alleyne G, Evans D, Claeson M et al (2006a). Disease control priorities in developing countries, 2nd edition. New York, NY: Oxford University Press.
- Jamison DT, Shahid-Salles SA, Jamison J, Lawn JE, Zupan J (2006b). Incorporating deaths near the time of birth into estimates of the global burden of disease. In: Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, editors. *Global burden of disease and risk factors.* Washington DC: World Bank and New York: Oxford University Press. p427-463.
- Kontis V Bennett JE, Mathers CD, Li G, Foreman K, Ezzati M. Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. *The Lancet* 2017, Apr 1; 389(10076): 1323-1335.
- Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, editors (2006). *Global burden of disease and risk factors.* Washington DC: World Bank and New York: Oxford University Press.  
(<http://www.ncbi.nlm.nih.gov/books/NBK11812/>, accessed on 7 November 2013)
- Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.*380(9859):2095–128.
- Lyttkens C (2003). Time to disable DALYs? *The European Journal of Health Economics.*4:195–202.
- Mathers CD, Iburg KM, Begg S (2006). Adjusting for dependent comorbidity in the calculation of healthy life expectancy. *Population Health Metrics.*4:4.
- Mathers CD, Lopez AD, Murray CJL (2006). The burden of disease and mortality by condition: data, methods and results for 2001. In: Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, editors. *Global burden of disease and risk factors.* Washington DC: World Bank and New York: Oxford University Press. p45–240.
- Murray CJL (1996). Rethinking DALYs. In: Murray CJL, Lopez AD, editors (1996). *The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020.* Cambridge: Harvard University Press.

Murray CJL, Lopez AD, editors (1996). The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press.

Murray C, Acharya A (2002). Age weights and discounting in health gaps reconsidered. In: Summary measures of population health: concepts, ethics, measurement and applications. Geneva: World Health Organization. p. 677–684.

Murray CJL, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C et al (2012a). GBD 2010: a multi-investigator collaboration for global comparative descriptive epidemiology. Lancet.380(9859): 2055–8.

Murray CJL, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C et al (2012b). GBD 2010: design, definitions, and metrics. Lancet;380: 2063–2066.

Murray CJL, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C et al (2012c). GBD 2010: design, definitions, and metrics [Supplementary appendix]. Lancet.380.

(<http://download.thelancet.com/mmcs/journals/lancet/PIIS0140673612618996/mmc1.pdf?id=a02f57d1811fcb77:-1b44796c:142333b8265:-259e1383841102443>, accessed 7 November 2013).

Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C et al (2012d). Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet.380:2197–2223.

Nord E (2013). Disability weights in the Global Burden of Disease 2010: unclear meaning and overstatement of international agreement. Health Policy.111(1):99–104.

Salomon JA, Murray CJL, Ustun TB, Chatterji S (2003). Health State Valuations in Summary Measures of Population Health. In: Murray CJL, Evans D, editors. Health systems performance assessment: debate, methods and empiricism. Geneva: World Health Organisation.

Salomon J (2008). Measurement of disability weights in the Global Burden of Disease 2005. GBD Disability Weights Expert Consultation, Seattle, 4–5 September 2008. Seattle: Institute for Health Metrics and Evaluation, University of Washington.

Salomon J (2013). Disability weights measurement in the Global Burden of Disease Study 2010 [slides]. Global Health Metrics and Evaluation Conference, Seattle, 18 June 2013. Seattle: Institute for Health Metrics and Evaluation, University of Washington. Available at <http://www.slideshare.net/IHME/disability-weights-measurement-in-the-global-burden-of-disease-study-2010>

Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A et al (2012a). Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet.380:2129–2143.

Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A et al (2012b). Common values in assessing health outcomes from disease and injury [Supplementary appendix]. Lancet.380.

(<http://download.thelancet.com/mmcs/journals/lancet/PIIS0140673612616808/mmc1.pdf?id=a02f57d1811fcb77:-1b44796c:142333b8265:-259e1383841102443>, accessed 7 November 2013).

Salomon JA, Wang H, Freeman MK, Vos T, Flaxman AD, Lopez AD et al (2012c). Healthy life expectancy for 187 countries, 1990–2010: a systematic analysis for the Global Burden Disease Study 2010. 380: 2144–2162.

Salomon JA, Haagsma JA, Davis A, Maertens de Noordhout C, Polinder S, Havelaar AH, Cassini A, Devleesschauwer B, Kretzschmar M, Speybroeck N, Murray CJL, Vos T (2015). Disability weights for the Global Burden of Disease 2013 study. The Lancet. 2015 Oct 19. doi:10.1016/S2214-109X(15)00069-8.

Schwarzinger M, Marlies EA Stouthard MEA, Burström K, Nord E (2003). Cross-national agreement on disability weights: the European Disability Weights Project. Population Health Metrics.1:9.

Stouthard, ME, Essink-Bot M, Bonsel G, Barendregt J, Kramers P (1997). Disability weights for diseases in the Netherlands. Rotterdam: Department of Public Health, Erasmus University.

Stouthard ME, Essink-Bot ML, Bonsel GL, on Behalf of the Dutch Disability Weights Group (2000). Disability weights for diseases—A modified protocol and results for a Western European Region. *European Journal of Public Health*.10: 24–30

Taylor HR, Jonas JB, Keeffe J, Leasher J, Naidoo Kovin, Pesudovs K et al (2013). Disability weights for vision disorders in Global Burden of Disease Study. *Lancet*.381:23–24.

Torgerson PR, Devleesschauwer B, Praet N, Speybroeck N, Willingham AL, et al. (2015) World Health Organization Estimates of the Global and Regional Disease Burden of 11 Foodborne Parasitic Diseases, 2010: A Data Synthesis. *PLoS Med* 12(12): e1001920. doi: 10.1371/journal.pmed.1001920

Tsuchiya A (2002). Age weighting and time discounting: technical imperative versus social choice. In: Summary measures of population health: concepts, ethics, measurement and applications. Geneva: World Health Organization.

United Nations Population Division (2024). World population prospects - the 2024 revision. New York: United Nations.

Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M et al (2012a). Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*.380:2163–2196.

Vos et al (2015). Supplement to: GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016; **388**: 1545–602.

Williams, A (1999). Calculating the global burden of disease: time for a strategic reappraisal. *Health Economics*.8:1-8.

World Bank (1993). World Development Report 1993. Washington: World Bank.

World Health Organization (2008). The global burden of disease: 2004 update. Geneva: World Health Organization.

World Health Organization (2009). Global health risks. Geneva: World Health Organization.

World Health Organization (2012). Measurement of healthy life expectancy and wellbeing: report of a technical meeting, Geneva 10-11 December 2012. Geneva: World Health Organization.

World Health Organization (2013a). Global health estimates for deaths by cause, age, and sex for years 2000-2011. Geneva: World Health Organization.

World Health Organization (2013b). WHO methods and data sources for global burden of disease estimates 2000-2011. Global Health Estimates Technical Paper WHO/HIS/HSI/GHE/2013.4.

World Health Organization (2014). Global health estimates for deaths by cause, age, and sex for years 2000-2012. Geneva: World Health Organization.

WHO 2015. WHO Estimates of the Global Burden of Foodborne Diseases. Geneva, World Health Organization; 2015.

WHO 2016. WHO methods and data sources for country-level causes of death 2000-2015 (Global Health Estimates Technical Paper WHO/HIS/HSI/GHE/2016.3)

WHO 2018. WHO methods and data sources for country-level causes of death 2000-2016 (Global Health Estimates Technical Paper WHO/HIS/IER/GHE/2018.3)

WHO 2018. WHO methods and data sources for global burden of disease estimates 2000-2016 (Global Health Estimates Technical Paper WHO/HIS/IER/GHE/2018.4)

WHO 2020. WHO methods and data sources for country-level causes of death 2000-2019 (Global Health Estimates Technical Paper WHO/DDI/DNA/GHE/2020.2)

WHO 2020. WHO methods and data sources for global burden of disease estimates 2000-2019 (Global Health Estimates Technical Paper WHO/DDI/DNA/GHE/2020.3)

WHO 2024. WHO methods and data sources for life tables 2000-2021 (Global Health Estimates Technical Paper WHO/DDI/DNA/GHE/2024.1)

WHO 2024. WHO methods and data sources for country-level causes of death 2000-2021 (Global Health Estimates Technical Paper WHO/DDI/DNA/GHE/2024.2)

WHO 2024. WHO methods and data sources for global burden of disease estimates 2000-2021 (Global Health Estimates Technical Paper WHO/DDI/DNA/GHE/2024.3)

World Health Organization (2024). Mortality database [online database]. Available at:

<https://platform.who.int/mortality>

## Annex Table A GHE cause categories and ICD-10 codes

GHE code	GHE cause name	ICD-10 codes
10	I. Communicable, maternal, perinatal and nutritional conditions <sup>a</sup>	A00-B99, D50-D53, D64.9, E00-E02, E40-E46, E50-E64, G00-G04, G14, H65-H66, J00-J22, N70-N73, O00-O99, P00-P96, U04, U07, U09-U10
20	A. Infectious and parasitic diseases	A00-B99, G00-G04, G14, N70-N73, P37.3, P37.4
30	1. Tuberculosis	A15-A19, B90
40	2. STDs excluding HIV	A50-A64, N70-N73
50	a. Syphilis	A50-A53
60	b. Chlamydia	A55-A56
70	c. Gonorrhoea	A54
80	d. Trichomoniasis	A59
85	e. Genital herpes	A60
90	f. Other STDs	A57-A58, A63-A64, N70-N73
100	3. HIV/AIDS	B20-B24
101	a. HIV resulting in TB	B20.0
102	b. HIV resulting in other diseases	B20-B24 (minus B20.0)
110	4. Diarrhoeal diseases <sup>b</sup>	A00, A01, A03, A04, A06-A09
120	5. Childhood-cluster diseases	A33-A37, B05
130	a. Whooping cough	A37
140	b. Diphtheria	A36
150	c. Measles	B05
160	d. Tetanus	A33-A35
170	6. Meningitis <sup>b</sup>	A39, G00, G03
180	7. Encephalitis <sup>b</sup>	A83-A86, B94.1, G04
185	8. Hepatitis	B15-B19 (minus B17.8)
186	a. Acute hepatitis A	B15
190	b. Acute hepatitis B	B16-B19 (minus B17.1, B17.2, B18.2, B18.8)
200	c. Acute hepatitis C	B17.1, B18.2
205	d. Acute hepatitis E	B17.2, B18.8
210	9. Parasitic and vector diseases	A71, A82, A90-A91, A95, B50-B57, B65, B67, B69, B73, B74.0-B74.2, P37.3-P37.4
220	a. Malaria	B50-B54, P37.3, P37.4
230	b. Trypanosomiasis	B56
240	c. Chagas disease	B57
250	d. Schistosomiasis	B65
260	e. Leishmaniasis	B55
270	f. Lymphatic filariasis	B74.0-B74.2
280	g. Onchocerciasis	B73
285	h. Cysticercosis	B69
295	i. Echinococcosis	B67
300	j. Dengue	A90-A91
310	k. Trachoma	A71
315	l. Yellow fever	A95
320	m. Rabies	A82
330	10. Intestinal nematode infections	B76-B81
340	a. Ascariasis	B77
350	b. Trichuriasis	B79
360	c. Hookworm disease	B76

<b>GHE code</b>	<b>GHE cause name</b>		<b>ICD-10 codes</b>
362	d. Food-bourne trematodes		B78, B80, B81
365	11. Leprosy		A30
370	12. Other infectious diseases		A02, A05, A20-A28, A31, A32, A38, A40-A49, A65-A70, A74-A79, A80-A81, A87-A89, A92-A99, B00-B04, B06-B09, B17.8, B25-B49, B58-B60, B64, B66, B68, B70-B72, B74.3-B74.9, B75, B82-B89, B91-B99 (minus B94.1), G14
380	<b>B. Respiratory infectious<sup>b</sup></b>		H65-H66, J00-J22, P23, U04
390	1. Lower respiratory infections		J09-J22, P23, U04, U07, U09-U10
395	2. COVID-19*		U07, U09-U10
400	3. Upper respiratory infections		J00-J06
410	4. Otitis media		H65-H66
420	<b>C. Maternal conditions</b>		O00-O99
490	<b>D. Neonatal conditions</b>		P00-P96 (minus P23, P37.3, P37.4)
500	1. Preterm birth complications <sup>b</sup>		P05, P07, P22, P27-P28
510	2. Birth asphyxia and birth trauma <sup>b</sup>		P03, P10-P15, P20-P21, P24-P26, P29
520	3. Neonatal sepsis and infections		P35-P39 (minus P37.3, P37.4)
530	4. Other neonatal conditions		P00-P02, P04, P08, P50-P96
540	<b>E. Nutritional deficiencies</b>		D50-D53, D64.9, E00-E02, E40-E46, E50-E64
550	1. Protein-energy malnutrition		E40-E46
560	2. Iodine deficiency		E00-E02
570	3. Vitamin A deficiency		E50
580	4. Iron-deficiency anaemia		D50, D64.9
590	5. Other nutritional deficiencies		D51-D53, E51-E64
600	<b>II. Noncommunicable diseases<sup>a</sup></b>		C00-C97, D00-D48, D55-D64 (minus D 64.9), D65-D89, E03-E07, E10-E34, E65-E88, F01-F99, G06-G98 (minus G14), H00-H61, H68-H93, I00-I99, J30-J98 (minus J69, J96), K00-K92, L00-L98, M00-M99, N00-N64, N75-N98, Q00-Q99, X41-X42, X44, X45, R95
610	<b>A. Malignant neoplasms<sup>c</sup></b>		C00-C97
620	1. Mouth and oropharynx cancers		C00-C14
621	a. Lip and oral cavity		C00-C08
622	b. Nasopharynx		C11
623	c. Other pharynx		C09-C10, C12-C14
630	2. Oesophagus cancer		C15
640	3. Stomach cancer		C16
650	4. Colon and rectum cancers		C18-C21
660	5. Liver cancer		C22
670	6. Pancreas cancer		C25
680	7. Trachea, bronchus, lung cancers		C33-C34
690	8. Melanoma and other skin cancers		C43-C44
691	a. Malignant skin melanoma		C43
692	b. Non-melanoma skin cancer		C44
700	9. Breast cancer		C50
710	10. Cervix uteri cancer <sup>d</sup>		C53
720	11. Corpus uteri cancer <sup>d</sup>		C54
730	12. Ovary cancer		C56
740	13. Prostate cancer		C61
742	14. Testicular cancer		C62
745	15. Kidney, renal pelvis and ureter cancer		C64-C66

<b>GHE code</b>	<b>GHE cause name</b>		<b>ICD-10 codes</b>
750	16.	Bladder cancer	C67
751	17.	Brain and nervous system cancers	C70-C72
752	18.	Gallbladder and biliary tract cancer	C23-C24
753	19.	Larynx cancer	C32
754	20.	Thyroid cancer	C73
755	21.	Mesothelioma	C45
760	22.	Lymphomas, multiple myeloma	C81-C90, C96
761	a.	Hodgkin lymphoma	C81
762	b.	Non-Hodgkin lymphoma	C82-C86, C96
763	c.	Multiple myeloma	C88, C90
770	23.	Leukaemia	C91-C95
780	24.	Other malignant neoplasms	C17, C26-C31, C37-C41, C46-C49, C51, C52, C57-C60, C63, C68, C69, C74-C75, C77-C79
790	<b>B. Other neoplasms</b>		D00-D48
800	<b>C. Diabetes mellitus</b>		E10-E14 (minus E10.2, E11.2, E12.2, E13.2, E14.2)
810	<b>D. Endocrine, blood, immune disorders</b>		D55-D64 (minus D64.9), D65-D89, E03-E07, E15-E34, E65-E88
811	1.	Thalassaemias	D56
812	2.	Sickle cell disorders and trait	D57
813	3.	Other haemoglobinopathies and haemolytic anaemias	D55, D58-D59
814	4.	Other endocrine, blood and immune disorders	D60-D64 (minus D64.9), D65-D89, E03-E07, E15-E34, E65-E88
820	<b>E. Mental and substance use disorders</b>		F04-F99, G72.1, Q86.0, X41-X42, X44, X45
830	1.	Depressive disorders	F32-F33, F34.1
831	a.	Major depressive disorder	F32-F33
832	b.	Dysthymia	F34.1
840	2.	Bipolar disorder	F30-F31
850	3.	Schizophrenia	F20-F29
860	4.	Alcohol use disorders	F10, G31.2, G72.1, Q86.0, X45
870	5.	Drug use disorders <sup>e</sup>	F11-F16, F18-F19 <sup>d</sup> , X41-X42, X44 <sup>d</sup>
871	a.	Opioid use disorders	F11, X42
872	b.	Cocaine use disorders	F14
873	c.	Amphetamine use disorders	F15
874	d.	Cannabis use disorders	F12
875	e.	Other drug use disorders	F13, F16, F18, X41
880	6.	Anxiety disorders	F40-F44
890	7.	Eating disorders	F50
900	8.	Autism and Asperger syndrome	F84
910	9.	Childhood behavioural disorders	F90-F92
911	a.	Attention deficit/hyperactivity syndrome	F90
912	b.	Conduct disorder	F91-F92
920	10.	Idiopathic intellectual disability	F70-F79
930	11.	Other mental and behavioural disorders	F04-F09, F17, F34-F39 (minus F34.1), F45-F48, F51-F69, F80-F83, F88-F89, F93-F99
940	<b>F. Neurological conditions</b>		F01-F03, G06-G98 (minus G14, G31.2, G72.1)
950	1.	Alzheimer disease and other dementias	F01-F03, G30-G31 (minus G31.2)
960	2.	Parkinson disease	G20-G21

<b>GHE code</b>	<b>GHE cause name</b>		<b>ICD-10 codes</b>
970	3.	Epilepsy	G40-G41
980	4.	Multiple sclerosis	G35
990	5.	Migraine	G43
1000	6.	Non-migraine headache	G44
1010	7.	Other neurological conditions	G06-G12, G23-G25, G36-G37, G45-G98 (minus G72.1)
1020	<b>G. Sense organ diseases</b>		H00-H61, H68-H93
1030	1.	Glaucoma	H40
1040	2.	Cataracts	H25-H26
1050	3.	Uncorrected refractive errors	H49-H52
1060	4.	Macular degeneration	H35.3
1070	5.	Other vision loss	H30-H35 (minus H35.3), H53-H54
1080	6.	Other hearing loss	H90-H91
1090	7.	Other sense organ disorders	H00-H21, H27, H43-H47, H55-H61, H68-H83, H92-H93
1100	<b>H. Cardiovascular diseases<sup>f,g</sup></b>		I00-I99
1110	1.	Rheumatic heart disease	I01-I09
1120	2.	Hypertensive heart disease	I11-I15
1130	3.	Ischaemic heart disease <sup>f,g</sup>	I20-I25
1140	4.	Stroke <sup>g</sup>	I60-I69
1150	5.	Cardiomyopathy, myocarditis, endocarditis	I30-I33, I38, I40, I42
1160	6.	Other circulatory diseases	I00, I26-I28, I34-I37, I44-I51, I70-I99
1170	<b>I. Respiratory diseases</b>		J30-J98 (minus J69, J96)
1180	1.	Chronic obstructive pulmonary disease <sup>f</sup>	J40-J44
1190	2.	Asthma	J45-J46
1200	3.	Other respiratory diseases	J30-J39, J47-J98 (minus J69, J96)
1210	<b>J. Digestive diseases</b>		K20-K92
1220	1.	Peptic ulcer disease	K25-K27
1230	2.	Cirrhosis of the liver	K70, K74
1240	3.	Appendicitis	K35-K37
1241	4.	Gastritis and duodenitis	K29
1242	5.	Paralytic ileus and intestinal obstruction	K56
1244	6.	Inflammatory bowel disease	K50-K52, K58.0
1246	7.	Gallbladder and biliary diseases	K80-K83
1248	8.	Pancreatitis	K85-K86
1250	9.	Other digestive diseases	K20-K22, K28, K30-K31, K38, K40-K46, K55, K57, K58.9, K59-K66, K71-K73, K75-K76, K90-K92
1260	<b>K. Genitourinary diseases</b>		E10.2-E10.29,E11.2-E11.29,E12.2,E13.2-E13.29,E14.2, N00-N64, N75-N76, N80-N98
1270	1.	Kidney diseases <sup>g</sup>	N00-N19, E10.2,E11.2,E12.2,E13.2,E14.2
1271	a.	Acute glomerulonephritis	N00-N01
1272	b.	Chronic kidney disease due to diabetes	E10.2, E11.2, E12.2, E13.2, E14.2
1273	c.	Other chronic kidney disease	N02-N19
1280	2.	Benign prostatic hyperplasia	N40
1290	3.	Urolithiasis	N20-N23
1300	4.	Other urinary diseases	N25-N39, N41-N45, N47-N51
1310	5.	Infertility	N46, N97
1320	6.	Gynecological diseases	N60-N64, N75-N76, N80-N96, N98

<b>GHE code</b>	<b>GHE cause name</b>	<b>ICD-10 codes</b>
1330	<b>L. Skin diseases</b>	L00-L98
1340	<b>M. Musculoskeletal diseases</b>	M00-M99
1350	1. Rheumatoid arthritis	M05-M06
1360	2. Osteoarthritis	M15-M19
1370	3. Gout	M10
1380	4. Back and neck pain	M45-M48, M50-M54
1390	5. Other musculoskeletal disorders	M00, M02, M08, M11-M13, M20-M43, M60-M99
1400	<b>N. Congenital anomalies</b>	Q00-Q99 (minus Q86.0)
1410	1. Neural tube defects	Q00, Q05
1420	2. Cleft lip and cleft palate	Q35-Q37
1430	3. Down syndrome	Q90
1440	4. Congenital heart anomalies <sup>i</sup>	Q20-Q28
1450	5. Other chromosomal anomalies	Q91-Q99
1460	6. Other congenital anomalies	Q01-Q04, Q06-Q18, Q30-Q34, Q38-Q89 (excluding Q86.0)
1470	<b>O. Oral conditions</b>	K00-K14
1480	1. Dental caries	K02
1490	2. Periodontal disease	K05
1500	3. Edentulism	-
1502	4. Other oral disorders	K00, K01, K03, K04, K06-K14
1505	<b>P. Sudden infant death syndrome</b>	R95
1510	<b>III. Injuries<sup>b</sup></b>	V01-Y89 (minus X41-X42, X44, X45)
1520	<b>A. Unintentional injuries</b>	V01-X40, X43, X46-59, Y40-Y86, Y88, Y89
1530	1. Road injury <sup>i</sup>	V01-V04, V06, V09-V80, V87, V89, V99, Y85
1540	2. poisonings	X40, X43, X46-X48, X49
1550	3. Falls	W00-W19
1560	4. Fire, heat and hot substances	X00-X19
1570	5. Drowning	W65-W74
1575	6. Exposure to mechanical forces	W20-W38, W40-W43, W45, W46, W49-W52, W75, W76
1580	7. Natural disasters	X33-X39
1590	8. Other unintentional injuries	Rest of V, W39, W44, W53-W64, W77-W99, X20-X32, X50-X59 (minus X59.4), Y40-Y86 (minus Y85), Y88, Y89
1600	<b>B. Intentional injuries</b>	X60-Y09, Y35-Y36, Y870, Y871
1610	1. Self-harm	X60-X84, Y870
1620	2. Interpersonal violence	X85-Y09, Y871
1630	3. Collective violence and legal intervention	Y35-Y36
1700	<b>IV. Other /pandemic-related**</b>	

—, not available

<sup>a</sup> Deaths coded to “Symptoms, signs and ill-defined conditions” (R00-R94, R96-R99), J69 and J96 are distributed proportionately to all causes within Group I and Group II.

<sup>b</sup> For deaths under age 5, refer to classification in Annex Tables E.

<sup>c</sup> Cancer deaths coded to ICD categories for malignant neoplasms of other and unspecified sites including those whose point of origin cannot be determined, and secondary and unspecified neoplasms (C76, C80, C97) were redistributed pro-rata across malignant neoplasm categories other than liver, pancreas, ovary and lung within each age-sex group, so that the category “Other malignant neoplasms” includes only malignant neoplasms of other specified sites.

<sup>d</sup> Deaths assigned to ICD code C55, cancer of the uterus, part unspecified, and distributed pro-rata to cervix uteri cancer and corpus uteri cancer.

<sup>e</sup> Deaths coded to F19 (Multiple and other drug use) and X44 (Accidental poisoning by other and unspecified drugs and medicines) have been redistributed to the GHE drug categories as described in Section 8.

<sup>f</sup> Deaths assigned to a number of so-called cardiovascular “garbage” codes are reassigned to other underlying causes of death. These include heart failure, ventricular dysrhythmias, generalized atherosclerosis and ill-defined descriptions and complications of heart disease. Relevant ICD-10 codes are I46, I47.2, I49.0, I50, I51.4, I51.5, I51.6, I51.9 and I70.9. These are reassigned mainly to ischemic heart disease, but also to cardiomyopathy, myocarditis, endocarditis, chronic obstructive pulmonary disease, congenital heart anomalies, as described in Section 4.

<sup>g</sup> Deaths assigned to essential hypertension (I10) were redistributed to ischemic heart disease, stroke, and kidney diseases.

<sup>h</sup> Injury deaths where the intent is not determined (Y10-Y34, Y87.2) are distributed proportionately to all causes below the group level for injuries.

<sup>i</sup> For countries with 3-digit ICD10 data, for “Road injury” use: Y85, V01-V04, V06, V09-V80, V87, V89 and V99. For countries with 4-digit ICD10 data, for “Road injury” use:

V01.1-V01.9, V02.1-V02.9, V03.1-V03.9, V04.1-V04.9, V06.1-V06.9, V09.2, V09.3, V10.3-V10.9, V11.3-V11.9, V12.3-V12.9, V13.3-V13.9, V14.3-V14.9, V15.4-V15.9, V16.4-V16.9, V17.4-V17.9, V18.4-V18.9, V19.4-V19.9, V20.3-V20.9, V21.3-V21.9, V22.3-V22.9, V23.3-V23.9, V24.3-V24.9, V25.3-V25.9, V26.3-V26.9, V27.3-V27.9, V28.3-V28.9, V29.4-V29.9, V30.4-V30.9, V31.4-V31.9, V32.4-V32.9, V33.4-V33.9, V34.4-V34.9, V35.4-V35.9, V36.4-V36.9, V37.4-V37.9, V38.4-V38.9, V39.4-V39.9, V40.4-V40.9, V41.4-V41.9, V42.4-V42.9, V43.4-V43.9, V44.4-V44.9, V45.4-V45.9, V46.4-V46.9, V47.4-V47.9, V48.4-V48.9, V49.4-V49.9, V50.4-V50.9, V51.4-V51.9, V52.4-V52.9, V53.4-V53.9, V54.4-V54.9, V55.4-V55.9, V56.4-V56.9, V57.4-V57.9, V58.4-V58.9, V59.4-V59.9, V60.4-V60.9, V61.4-V61.9, V62.4-V62.9, V63.4-V63.9, V64.4-V64.9, V65.4-V65.9, V66.4-V66.9, V67.4-V67.9, V68.4-V68.9, V69.4-V69.9, V70.4-V70.9, V71.4-V71.9, V72.4-V72.9, V73.4-V73.9, V74.4-V74.9, V75.4-V75.9, V76.4-V76.9, V77.4-V77.9, V78.4-V78.9, V79.4-V79.9, V80.3-V80.5, V81.1, V82.1, V82.8-V82.9, V83.0-V83.3, V84.0-V84.3, V85.0-V85.3, V86.0-V86.3, V87.0-V87.9, V89.2-V89.3, V89.9, V99, X59.4 and Y85.

\* Deaths directly caused by COVID-19, with ICD-10 codes including U07, U09-U10.

\*\* To reconcile deaths associated with COVID-19 excess mortality and cause-specific pandemic-related deaths, GBD2021 introduced a measure of other pandemic related mortality (OPRM) to capture all deaths due to the pandemic which were not specifically caused by COVID-19 or the indirect COVID causes. It is equal to the difference between excess mortality and the sum of COVID-19 specific deaths, measles, lower respiratory infection (LRI), and pertussis.

## Annex Table B Health states and lay descriptions used in the GBD study.

Health state	Lay description
<b>Infectious disease</b>	
Infectious disease, acute episode, mild	has a low fever and mild discomfort , but no difficulty with daily activities.
Infectious disease, acute episode, moderate	has a fever and aches, and feels weak, which causes some difficulty with daily activities.
Infectious disease, acute episode, severe	has a high fever and pain, and feels very weak, which causes great difficulty with daily activities.
Infectious disease, post-acute consequences (fatigue, emotional lability, insomnia)	is always tired and easily upset. The person feels pain all over the body and is depressed.
Diarrhea, mild	has diarrhea three or more times a day with occasional discomfort in the belly.
Diarrhea, moderate	has diarrhea three or more times a day, with painful cramps in the belly and feeling thirsty
Diarrhea, severe	has diarrhea three or more times a day with severe belly cramps. The person is very thirsty and feels nauseous and tired.
Epididymo-orchitis	has swelling and tenderness in the testicles and pain during urination.
Herpes zoster	has a blistering skin rash that causes pain, with some burning and itching.
HIV cases, symptomatic, pre-AIDS	has weight loss, fatigue, and frequent infections.
HIV/AIDS cases, receiving ARV treatment	has occasional fevers and infections. The person takes daily medication that sometimes causes diarrhea.
AIDS cases, not receiving ARV treatment	has severe weight loss, weakness, fatigue, cough and fever, and frequent infections, skin rashes and diarrhea.
Intestinal nematode infections, symptomatic	has cramping pain and a bloated feeling in the belly.
Lymphatic filariasis, symptomatic	has swollen legs with hard and thick skin, which causes difficulty in moving around.
Ear pain	has an ear-ache that causes some difficulty with daily activities.
Tuberculosis, not HIV infected	has a persistent cough and fever, is short of breath, feels weak, and has lost a lot of weight.
Tuberculosis, HIV infected	has a persistent cough and fever, shortness of breath, night sweats, weakness and fatigue and severe weight loss.
<b>Cancer</b>	
Cancer, diagnosis and primary therapy	has pain, nausea, fatigue, weight loss and high anxiety.
Cancer, metastatic	has severe pain, extreme fatigue, weight loss and high anxiety.
Mastectomy	had one of her breasts removed and sometimes has pain or swelling in the arms.
Stoma	has a pouch attached to an opening in the belly to collect and empty stools.
Terminal phase, with medication (for cancers, end-stage kidney/liver disease)	has lost a lot of weight and regularly uses strong medication to avoid constant pain. The person has no appetite, feels nauseous, and needs to spend most of the day in bed.

Health state	Lay description
Terminal phase, without medication (for cancers, end-stage kidney/liver disease)	has lost a lot of weight and has constant pain. The person has no appetite, feels nauseous, and needs to spend most of the day in bed.
<b><i>Cardiovascular and circulatory disease</i></b>	
Acute myocardial infarction, days 1-2	has severe chest pain that becomes worse with any physical activity,. The person feels nauseous, short of breath, and very anxious.
Acute myocardial infarction, days 3-28	gets short of breath after heavy physical activity, and tires easily, but has no problems when at rest. The person has to take medication every day and has some anxiety.
Angina pectoris, mild	has chest pain that occurs with strenuous physical activity, such as running or lifting heavy objects. After a brief rest, the pain goes away.
Angina pectoris, moderate	has chest pain that occurs with moderate physical activity, such as walking uphill or more than half a kilometer (around a quarter-mile) on level ground. After a brief rest, the pain goes away.
Angina pectoris, severe	has chest pain that occurs with minimal physical activity, such as walking only a short distance. After a brief rest, the pain goes away. The person avoids most physical activities because of the pain.
Cardiac conduction disorders and cardiac dysrhythmias	has periods of rapid and irregular heartbeats and occasional fainting.
Claudication	has cramping pains in the legs after walking a medium distance. The pain goes away after a short rest.
Heart failure, mild	is short of breath and easily tires with moderate physical activity, such as walking uphill or more than a quarter-mile on level ground. The person feels comfortable at rest or during activities requiring less effort.
Heart failure, moderate	is short of breath and easily tires with minimal physical activity, such as walking only a short distance. The person feels comfortable at rest but avoids moderate activity.
Heart failure, severe	is short of breath and feels tired when at rest. The person avoids any physical activity, for fear of worsening the breathing problems.
Stroke, long-term consequences, mild	has some difficulty in moving around and some weakness in one hand, but is able to walk without help.
Stroke, long-term consequences, moderate	has some difficulty in moving around, and in using the hands for lifting and holding things, dressing and grooming.
Stroke, long-term consequences, moderate plus cognition problems	has some difficulty in moving around, in using the hands for lifting and holding things, dressing and grooming, and in speaking. The person is often forgetful and confused.
Stroke, long-term consequences, severe	is confined to bed or a wheelchair, has difficulty speaking and depends on others for feeding, toileting and dressing.
Stroke, long-term consequences, severe plus cognition problems	is confined to bed or a wheelchair, depends on others for feeding, toileting and dressing, and has difficulty speaking, thinking clearly and remembering things.
<b><i>Diabetes, digestive and genitourinary disease</i></b>	
Diabetic neuropathy	has pain, tingling and numbness in the arms, legs, hands and feet. The person sometimes gets cramps and muscle weakness.
Chronic kidney disease (stage IV)	tires easily, has nausea, reduced appetite and difficulty sleeping.
End-stage renal disease, with kidney transplant	sometimes feels tired and down, and has some difficulty with daily activities.
End-stage renal disease, on dialysis	is tired and has itching, cramps, headache, joint pains and shortness of breath. The

<b>Health state</b>	<b>Lay description</b>
Decompensated cirrhosis of the liver	person needs intensive medical care every other day lasting about half a day.
Gastric bleeding	has a swollen belly and swollen legs. The person feels weakness, fatigue and loss of appetite.
Crohn disease or ulcerative colitis	vomits blood and feels nauseous.
Benign prostatic hypertrophy, symptomatic cases	has cramping abdominal pain, has diarrhea several times a day, and feels very tired for two months every year. When the person does not have symptoms, there is anxiety about them returning.
Impotence	feels the urge to urinate frequently, but when passing urine it comes out slowly and sometimes is painful.
Stress incontinence	loses small amounts of urine without meaning to when coughing, sneezing, laughing or during physical exercise.
Urinary incontinence	has difficulty in obtaining or maintaining an erection.
Infertility, primary	cannot control urinating.
Infertility, secondary	wants to have a child and has a fertile partner, but the couple cannot conceive.
	has at least one child, and wants to have more children. The person has a fertile partner, but the couple cannot conceive.

### *Chronic respiratory diseases*

Asthma, controlled	has wheezing and cough once a month, which does not cause difficulty with daily activities.
Asthma, partially controlled	has wheezing and cough once a week, which causes some difficulty with daily activities.
Asthma, uncontrolled	has wheezing, cough and shortness of breath more than twice a week, which causes difficulty with daily activities and sometimes wakes the person at night.
COPD and other chronic respiratory problems, mild	has cough and shortness of breath after heavy physical activity, but is able to walk long distances and climb stairs.
COPD and other chronic respiratory problems, moderate	has cough, wheezing and shortness of breath, even after light physical activity. The person feels tired and can walk only short distances or climb only a few stairs.
COPD and other chronic respiratory problems, severe	has cough, wheezing and shortness of breath all the time. The person has great difficulty walking even short distances or climbing any stairs, feels tired when at rest, and is anxious.

### *Neurological conditions*

Dementia, mild	has some trouble remembering recent events, and finds it hard to concentrate and make decisions and plans.
Dementia, moderate	has memory problems and confusion, feels disoriented, at times hears voices that are not real, and needs help with some daily activities.
Dementia, severe	has complete memory loss; no longer recognizes close family members; and requires help with all daily activities.
Headache, migraine	has severe, throbbing head pain and nausea that cause great difficulty in daily activities and sometimes confine the person to bed. Moving around, light, and noise make it worse.
Back pain, severe, without leg pain	has severe back pain, which causes difficulty dressing, sitting, standing, walking, and lifting things. The person sleeps poorly and feels worried.

Health state	Lay description
Headache, tension-type	has a moderate headache that also affects the neck, which causes difficulty in daily activities.
Headache, medication overuse	has daily headaches, felt as dull pain and often lasting all day, with poor sleep, nausea and fatigue. The person takes medicine for the headaches, which provides little relief but is needed to avoid having worse symptoms.
Multiple sclerosis, mild	has mild loss of feeling in one hand, is a little unsteady while walking, has slight loss of vision in one eye, and often needs to urinate urgently.
Multiple sclerosis, moderate	needs help walking, has difficulty with writing and arm coordination, has loss of vision in one eye and cannot control urinating.
Multiple sclerosis, severe	has slurred speech and difficulty swallowing. The person has weak arms and hands, very limited and stiff leg movement, has loss of vision in both eyes and cannot control urinating.
Epilepsy, less severe (seizures < once per month)	has sudden seizures two to five times a year, with violent muscle contractions and stiffness, loss of consciousness, and loss of urine or bowel control.
Epilepsy, severe (seizures >= once per month)	has sudden seizures one or more times each month, with violent muscle contractions and stiffness, loss of consciousness, and loss of urine or bowel control. Between seizures the person has memory loss and difficulty concentrating.
Parkinson disease, mild	has mild tremors and moves a little slowly, but is able to walk and do daily activities without assistance.
Parkinson disease, moderate	has moderate tremors and moves slowly, which causes some difficulty in walking and daily activities. The person has some trouble swallowing, talking, sleeping, and remembering things.
Parkinson disease, severe	has severe tremors and moves very slowly, which causes great difficulty in walking and daily activities. The person falls easily and has a lot of difficulty talking, swallowing, sleeping, and remembering things.

### *Mental, behavioral and substance use disorders*

Alcohol use disorder, very mild	drinks alcohol daily and has difficulty controlling the urge to drink. When sober, the person functions normally.
Alcohol use disorder, mild	drinks a lot of alcohol and sometimes has difficulty controlling the urge to drink. While intoxicated, the person has difficulty performing daily activities.
Alcohol use disorder, moderate	drinks a lot, gets drunk almost every week and has great difficulty controlling the urge to drink. Drinking and recovering cause great difficulty in daily activities, sleep loss, and fatigue.
Alcohol use disorder, severe	gets drunk almost every day and is unable to control the urge to drink. Drinking and recovering replace most daily activities. The person has difficulty thinking, remembering and communicating, and feels constant pain and fatigue.
Fetal alcohol syndrome, mild	is a little slow in developing physically and mentally, which causes some difficulty in learning but no other difficulties in daily activities.
Fetal alcohol syndrome, moderate	is slow in developing physically and mentally, which causes some difficulty in daily activities.
Fetal alcohol syndrome, severe	is very slow in developing physically and mentally, which causes great difficulty in daily activities.
Cannabis dependence	uses marijuana daily and has difficulty controlling the habit. The person sometimes has mood swings, anxiety and hallucinations, and has some difficulty in daily activities.
Cannabis dependence, mild	uses marijuana at least once a week and has some difficulty controlling the habit.

<b>Health state</b>	<b>Lay description</b>
Amphetamine dependence	uses stimulants (drugs) and has difficulty controlling the habit. The person sometimes has depression, hallucinations and mood swings, and has difficulty in daily activities.
Amphetamine dependence, mild	uses stimulants (drugs) at least once a week and has some difficulty controlling the habit. When not using, the person functions normally.
Cocaine dependence	uses cocaine and has difficulty controlling the habit. The person sometimes has mood swings, anxiety, paranoia, hallucinations and sleep problems, and has some difficulty in daily activities.
Cocaine dependence, mild	uses cocaine at least once a week and has some difficulty controlling the habit. When not using, the person functions normally.
Heroin and other opioid dependence	uses heroin daily and has difficulty controlling the habit. When the effects wear off, the person feels severe nausea, agitation, vomiting and fever. The person has a lot of difficulty in daily activities.
Heroin and other opioid dependence, mild	uses heroin (or methadone) daily and has difficulty controlling the habit. When not using, the person functions normally.
Anxiety disorders, mild	feels mildly anxious and worried, which makes it slightly difficult to concentrate, remember things, and sleep. The person tires easily but is able to perform daily activities.
Anxiety disorders, moderate	feels anxious and worried, which makes it difficult to concentrate, remember things, and sleep. The person tires easily and finds it difficult to perform daily activities.
Anxiety disorders, severe	constantly feels very anxious and worried, which makes it difficult to concentrate, remember things and sleep. The person has lost pleasure in life and thinks about suicide.
Major depressive disorder, mild episode	feels persistent sadness and has lost interest in usual activities. The person sometimes sleeps badly, feels tired, or has trouble concentrating but still manages to function in daily life with extra effort.
Major depressive disorder, moderate episode	has constant sadness and has lost interest in usual activities. The person has some difficulty in daily life, sleeps badly, has trouble concentrating, and sometimes thinks about harming himself (or herself).
Major depressive disorder, severe episode	has overwhelming, constant sadness and cannot function in daily life. The person sometimes loses touch with reality and wants to harm or kill himself (or herself).
Bipolar disorder, manic episode	is hyperactive, hears and believes things that are not real, and engages in impulsive and aggressive behavior that endanger the person and others.
Bipolar disorder, residual state	has mild mood swings, irritability and some difficulty with daily activities.
Schizophrenia, acute state	hears and sees things that are not real and is afraid, confused, and sometimes violent. The person has great difficulty with communication and daily activities, and sometimes wants to harm or kill himself (or herself).
Anorexia nervosa	feels an overwhelming need to starve and exercises excessively to lose weight. The person is very thin, weak and anxious.
Bulimia nervosa	has uncontrolled overeating followed by guilt, starving, and vomiting to lose weight.
Attention deficit hyperactivity disorder	is hyperactive and has difficulty concentrating, remembering things, and completing tasks.
Conduct disorder	has frequent behavior problems, which are sometimes violent. The person often has difficulty interacting with other people and feels irritable.
Asperger syndrome	has difficulty interacting with other people, and is slow to understand or respond to questions. The person is often preoccupied with one thing and has some difficulty

<b>Health state</b>	<b>Lay description</b>
	with basic daily activities.
Autism	has severe problems interacting with others and difficulty understanding simple questions or directions. The person has great difficulty with basic daily activities and becomes distressed by any change in routine.
Borderline intellectual functioning	is slow in learning at school. As an adult, the person has some difficulty doing complex or unfamiliar tasks but otherwise functions independently.
Intellectual disability / mental retardation, mild	has low intelligence and is slow in learning at school. As an adult, the person can live independently, but often needs help to raise children and can only work at simple supervised jobs.
Intellectual disability / mental retardation, moderate	has low intelligence, and is slow in learning to speak and to do even simple tasks. As an adult, the person requires a lot of support to live independently and raise children. The person can only work at the simplest supervised jobs.
Intellectual disability / mental retardation, severe	has very low intelligence and cannot speak more than a few words, needs constant supervision and help with most daily activities, and can do only the simplest tasks.
Intellectual disability / mental retardation, profound	has very low intelligence, has almost no language, and does not understand even the most basic requests or instructions. The person requires constant supervision and help for all activities.

### ***Hearing and vision loss***

Hearing loss, mild	has great difficulty hearing and understanding another person talking in a noisy place (for example, on an urban street).
Hearing loss, moderate	is unable to hear and understand another person talking in a noisy place (for example, on an urban street), and has difficulty hearing another person talking even in a quiet place or on the phone.
Hearing loss, severe	is unable to hear and understand another person talking, even in a quiet place, and unable to take part in a phone conversation. Difficulties with communicating and relating to others cause emotional impact at times (for example worry or depression).
Hearing loss, profound	is unable to hear and understand another person talking, even in a quiet place, is unable to take part in a phone conversation, and has great difficulty hearing anything in any other situation. Difficulties with communicating and relating to others often cause worry, depression or loneliness.
Hearing loss, complete	cannot hear at all in any situation, including even the loudest sounds, and cannot communicate verbally or use a phone. Difficulties with communicating and relating to others often cause worry, depression or loneliness.
Hearing loss, mild, with ringing	has great difficulty hearing and understanding another person talking in a noisy place (for example, on an urban street), and sometimes has annoying ringing in the ears.
Hearing loss, moderate, with ringing	is unable to hear and understand another person talking in a noisy place (for example, on an urban street), has difficulty hearing another person talking even in a quiet place or on the phone, and has annoying ringing in the ears for 5 minutes at a time, almost every day.
Hearing loss, severe, with ringing	is unable to hear and understand another person talking, even in a quiet place, is unable to take part in a phone conversation, and has annoying ringing in the ears for more than 5 minutes at a time, almost every day. Difficulties with communicating and relating to others cause emotional impact at times (for example worry or depression).
Hearing loss, profound, with ringing	is unable to hear and understand another person talking, even in a quiet place, is unable to take part in a phone conversation, has great difficulty hearing anything in any other situation, and has annoying ringing in the ears for more than 5 minutes at a time, several times a day. Difficulties with communicating and relating to others often cause worry, depression, or loneliness.
Hearing loss, complete, with ringing	cannot hear at all in any situation, including even the loudest sounds, and cannot

<b>Health state</b>	<b>Lay description</b>
	communicate verbally or use a phone, and has very annoying ringing in the ears for more than half of the day. Difficulties with communicating and relating to others often cause worry, depression or loneliness.
Distance vision, monocular	is blind in one eye and has difficulty judging distances
Distance vision, mild impairment	has some difficulty with distance vision, for example reading signs, but no other problems with eyesight.
Distance vision, moderate impairment	has vision problems that make it difficult to recognize faces or objects across a room.
Distance vision, severe impairment	has severe vision loss, which causes difficulty in daily activities, some emotional impact (for example worry), and some difficulty going outside the home without assistance.
Distance vision blindness	is completely blind, which causes great difficulty in some daily activities, worry and anxiety, and great difficulty going outside the home without assistance.
Presbyopia	has difficulty seeing things that are nearer than 3 feet, but has no difficulty with seeing things at a distance.

### ***Musculoskeletal disorders***

Low back pain, mild	has mild back pain, which causes some difficulty dressing, standing, and lifting things.
Low back pain, moderate	has moderate back pain, which causes difficulty dressing, sitting, standing, walking, and lifting things.
Back pain, severe, with leg pain	has severe back and leg pain, which causes difficulty dressing, sitting, standing, walking, and lifting things. The person sleeps poorly and feels worried.
Neck pain, mild	has neck pain, and has difficulty turning the head and lifting things.
Back pain, most severe, with leg pain	has constant back and leg pain, which causes difficulty dressing, sitting, standing, walking, and lifting things. The person sleeps poorly, is worried, and has lost some enjoyment in life.
Neck pain, moderate	has constant neck pain, and has difficulty turning the head, holding arms up, and lifting things
Neck pain, severe	has severe neck pain, and difficulty turning the head and lifting things. The person gets headaches and arm pain, sleeps poorly, and feels tired and worried.
Neck pain, most severe	has constant neck pain and arm pain, and difficulty turning the head, holding arms up, and lifting things. The person gets headaches, sleeps poorly, and feels tired and worried.
Musculoskeletal problems, lower limbs, mild	has pain in the leg, which causes some difficulty running, walking long distances, and getting up and down.
Musculoskeletal problems, lower limbs, moderate	has moderate pain in the leg, which makes the person limp, and causes some difficulty walking, standing, lifting and carrying heavy things, getting up and down and sleeping.
Musculoskeletal problems, lower limbs, severe	has severe pain in the leg, which makes the person limp and causes a lot of difficulty walking, standing, lifting and carrying heavy things, getting up and down, and sleeping.
Musculoskeletal problems, upper limbs, mild	has mild pain and stiffness in the arms and hands. The person has some difficulty lifting, carrying and holding things.
Musculoskeletal problems, upper limbs, moderate	has moderate pain and stiffness in the arms and hands, which causes difficulty lifting, carrying, and holding things, and trouble sleeping because of the pain.
Musculoskeletal problems, generalized, moderate	has pain and deformity in most joints, causing difficulty moving around, getting up and down, and using the hands for lifting and carrying. The person often feels fatigued.

Health state	Lay description
Musculoskeletal problems, generalized, severe	has severe, constant pain and deformity in most joints, causing difficulty moving around, getting up and down, eating, dressing, lifting, carrying and using the hands. The person often feels sadness, anxiety and extreme fatigue.
Gout, acute	has severe pain and swelling in the leg, making it very difficult to get up and down, stand, walk, lift, and carry heavy things. The person has trouble sleeping because of the pain.
<b>Injuries</b>	
Amputation of finger(s), excluding thumb (long term, with treatment)	has lost part of the fingers of one hand, causing difficulties in using the hand, pain, and tingling in the stumps.
Amputation of thumb (long term)	has lost one thumb, causing some difficulty in using the hand, pain, and tingling in the stump.
Amputation of one upper limb (long term, with or without treatment)	has lost one hand and part of the arm, leaving pain and tingling in the stump and flashbacks from the injury. The person requires help lifting objects and in daily activities such as cooking.
Amputation of both upper limbs (long term, with treatment)	has lost part of both arms, leaving pain and tingling in the stumps and flashbacks from the injury. The person has comfortable artificial arms and is mostly independent.
Amputation of both upper limbs (long term, without treatment)	has lost part of both arms, leaving pain and tingling in the stumps and flashbacks from the injury. The person needs help with basic daily activities such as eating and using the toilet.
Amputation of toe	has lost one toe, leaving occasional pain and tingling in the stump.
Amputation of one lower limb (long term, with treatment)	has lost part of one leg, leaving pain and tingling in the stump. The person has a comfortable artificial leg and only slight difficulties moving around.
Amputation of one lower limb (long term, without treatment)	has lost part of one leg, leaving pain and tingling in the stump. The person does not have an artificial leg, has frequent sores, and uses crutches.
Amputation of both lower limbs (long term, with treatment)	has lost part of both legs, leaving pain and tingling in the stumps. The person has two comfortable artificial legs, which allow for movement.
Amputation of both lower limbs (long term, without treatment)	has lost part of both legs, leaving pain, tingling, and frequent sores in the stumps. The person has great difficulty moving around and has episodes of depression, anxiety and flashbacks to the injury.
Burns, <20% total burned surface area without lower airway burns (short term, with or without treatment)	has a burn on part of the body. Parts of the burned area are painful, and other parts have lost feeling.
Burns, <20% total burned surface area or <10% total burned surface area if head/neck or hands/wrist involved (long term, with or without treatment)	has scars caused by a burn. The scars are sometimes painful and itchy.
Burns, ≥20% total burned surface area (short term, with or without treatment)	has a painful burn over a large part of the body. Parts of the burned area have lost feeling, and the person feels anxious and unwell.
Burns, ≥20% total burned surface area or ≥10% total burned surface area if head/neck or hands/wrist involved (long term, with treatment)	has scars caused by burns over a large part of the body. The scars are frequently painful and itchy, and the person is often sad.
Burns, ≥20% total burned surface area or ≥10% total burned surface area if head/neck or hands/wrist involved (long term, without treatment)	has severe, disfiguring and itchy scars caused by burns over a large part of the body. The person cannot move some joints, feels sad, and has great difficulty with self-care such as dressing and toileting.
Lower airway burns (with or without	has a burn in the throat and lungs, which causes great difficulty breathing and a lot of

<b>Health state</b>	<b>Lay description</b>
treatment)	anxiety.
Crush injury (short or long term, with or without treatment)	had part of the body crushed, leaving pain, swelling, tingling and limited feeling in the affected area.
Dislocation of hip (long term, with or without treatment)	walks with a limp and feels discomfort when walking.
Dislocation of knee (long term, with or without treatment)	has a knee out of joint, causing pain and difficulty moving the knee, which sometimes gives way. The person needs crutches for walking and help with self-care such as dressing.
Dislocation of shoulder (long term, with or without treatment)	has a shoulder that is out of joint, causing pain and difficulty moving. The person has difficulty with daily activities such as dressing and cooking.
Other injuries of muscle and tendon (includes sprains, strains and dislocations other than shoulder, knee, hip)	has a strained muscle that causes pain and swelling.
Drowning and nonfatal submersion (short or long term, with or without treatment)	has breathlessness, anxiety, cough, and vomiting.
Fracture of clavicle, scapula or humerus (short or long term, with or without treatment)	has a broken shoulder bone, which is painful and swollen. The person cannot use the affected arm and has difficulty with getting dressed.
Fracture of face bone (short or long term, with or without treatment)	has a broken cheek bone, broken nose, and chipped teeth, with swelling and severe pain.
Fracture of foot bones (short term, with or without treatment)	has a broken foot bone, which causes pain, swelling, and difficulty walking.
Fracture of foot bones (long term, without treatment)	had a broken foot in the past that did not heal properly. The person now has pain in the foot and has some difficulty walking.
Fracture of hand (short term, with or without treatment)	has a broken hand, causing pain and swelling.
Fracture of hand (long term, without treatment)	has stiffness in the hand and a weak grip.
Fracture of neck of femur (short term, with or without treatment)	has broken a hip and is in pain. The person cannot stand or walk, and needs help washing, dressing, and going to the toilet.
Fracture of neck of femur (long term, with treatment)	had a broken hip in the past, which was fixed with treatment. The person can only walk short distances, has discomfort when moving around, and has some difficulty in daily activities.
Fracture of neck of femur (long term, without treatment)	had a broken hip bone in the past, which was never treated and did not heal properly. The person cannot get out of bed and needs help washing and going to the toilet.
Fracture, other than femoral neck (short term, with or without treatment)	has a broken thigh bone. The person has severe pain and swelling and cannot walk.
Fracture, other than femoral neck (long term, without treatment)	had a broken thigh bone in the past, which was never treated and did not heal properly. The person now has a limp and discomfort when walking.
Fracture of patella, tibia or fibula or ankle (short term, with or without treatment)	has a broken shin bone, which causes severe pain, swelling, and difficulty walking.
Fracture of patella, tibia or fibula or ankle (long term, with or without treatment)	had a broken shin bone in the past that did not heal properly. The person has pain in the knee and ankle, and has difficulty walking.
Fracture of pelvis (short term)	has a broken pelvis bone, with swelling and bruising. The person has severe pain, and cannot walk or do daily activities.

Health state	Lay description
Fracture of pelvis (long term)	had a broken pelvis in the past and now walks with a limp. There is often pain in the back and groin, and when urinating and sitting for a long time.
Fracture of radius or ulna (short term, with or without treatment)	has a broken forearm, which causes severe pain, swelling, and limited movement.
Fracture of radius or ulna (long term, without treatment)	had a broken forearm in the past that did not heal properly, causing some pain and limited movement in the elbow and wrist. The person has difficulty with daily activities such as dressing.
Fracture of skull (short or long term, with or without treatment)	has a broken skull, but does not have brain damage. The broken area is painful and swollen.
Fracture of sternum and/or fracture of one or two ribs (short term, with or without treatment)	has a broken rib that causes severe pain in the chest, especially when breathing in. The person has difficulty with daily activities such as dressing.
Fracture of vertebral column (short or long term, with or without treatment)	has broken back bones and is in pain, but still has full use of arms and legs.
Fractures, treated (long term)	has slight pain in a bone that was broken in the past.
Injured nerves (short term)	has a nerve injury, which causes difficulty moving and some loss of feeling in the affected area.
Injured nerves (long term)	had a nerve injury in the past, which continues to cause some difficulty moving. The person often injures the affected part because it is numb.
Injury to eyes (short term)	has an injury to one eye, which causes pain and difficulty seeing.
Severe traumatic brain injury, short term (with or without treatment)	cannot concentrate and has headaches, memory problems, dizziness, and feels angry.
Concussion	has headaches, dizziness, nausea and difficulty concentrating.
Traumatic brain injury, long-term consequences, minor (with or without treatment)	has episodes of headaches, memory problems, and difficulty concentrating.
Traumatic brain injury, long-term consequences, moderate (with or without treatment)	has frequent headaches, memory problems, difficulty concentrating, and dizziness. The person is often anxious and moody.
Traumatic brain injury, long-term consequences, severe (with or without treatment)	cannot think clearly and has frequent headaches, memory problems, difficulty concentrating and dizziness. The person is often anxious and moody, and depends on others for feeding, toileting, dressing and walking.
Open wound (short term, with or without treatment)	has a cut in the skin, which causes pain and numbness around the cut.
Poisoning (short term with or without treatment)	has drowsiness, stomach pain and vomiting.
Severe chest injury (long term, with or without treatment)	had a severe chest injury in the past that has now healed. The person still gets breathless when walking and feels discomfort in the chest.
Severe chest injury (short term, with or without treatment)	has a serious chest injury, which causes severe pain, shortness of breath and anxiety.
Spinal cord lesion below neck level (treated)	is paralyzed from the waist down, cannot feel or move the legs and has difficulties with urine and bowel control. The person uses a wheelchair to move around.
Spinal cord lesion below neck level (untreated)	is paralyzed from the waist down and cannot feel or move the legs. Legs are in fixed, bent positions, and the person gets frequent infections and pressure sores.

<b>Health state</b>	<b>Lay description</b>
Spinal cord lesion at neck level (treated)	is paralyzed from the neck down and cannot feel or move the arms and legs.
Spinal cord lesion at neck level (untreated)	is paralyzed from the neck down and cannot feel or move the arms and legs. Arms and legs are in fixed, bent positions, and the person gets frequent infections and pressure sores.
<b><i>Other</i></b>	
Abdominopelvic problem, mild	has some pain in the belly that causes nausea but does not interfere with daily activities.
Abdominopelvic problem, moderate	has pain in the belly and feels nauseous. The person has difficulties with daily activities.
Abdominopelvic problem, severe	has severe pain in the belly and feels nauseous. The person is anxious and unable to carry out daily activities.
Anemia, mild	feels slightly tired and weak at times, but this does not interfere with normal daily activities.
Anemia, moderate	feels moderate fatigue, weakness, and shortness of breath after exercise, making daily activities more difficult.
Anemia, severe	feels very weak, tired and short of breath, and has problems with activities that require physical effort or deep concentration.
Thrombocytopenic purpura	easily bruises and sometimes bleeds from the gums and nose; feels weak and has some difficulty with daily activities.
Periodontitis	has minor bleeding of the gums from time to time, with mild discomfort.
Dental caries, symptomatic	has a toothache, which causes some difficulty in eating.
Severe tooth loss	has lost more than 20 teeth including front and back, and has great difficulty in eating meat, fruits, and vegetables.
Disfigurement, level 1	has a slight, visible physical deformity that others notice, which causes some worry and discomfort.
Disfigurement, level 2	has a visible physical deformity that causes others to stare and comment. As a result, the person is worried and has trouble sleeping and concentrating.
Disfigurement, level 3	has an obvious physical deformity that makes others uncomfortable, which causes the person to avoid social contact, feel worried, sleep poorly, and think about suicide.
Disfigurement, level 1 with itch/pain	has a slight, visible physical deformity that is sometimes sore or itchy. Others notice the deformity, which causes some worry and discomfort.
Disfigurement, level 2, with itch/pain	has a visible physical deformity that is sore and itchy. Other people stare and comment, which causes the person to worry. The person has trouble sleeping and concentrating.
Disfigurement, level 3, with itch/pain	has an obvious physical deformity that is very painful and itchy. The physical deformity makes others uncomfortable, which causes the person to avoid social contact, feel worried, sleep poorly, and think about suicide.
Generic uncomplicated disease: worry and daily medication	has a chronic disease that requires medication every day and causes some worry but minimal interference with daily activities.
Generic uncomplicated disease: anxiety about diagnosis	has a disease diagnosis that causes some worry but minimal interference with daily activities.
Hyperthyroidism	feels nervous, has palpitations, sweats a lot and has difficulty sleeping.

<b>Health state</b>	<b>Lay description</b>
Hypothyroidism	has low energy and feels cold.
Iodine-deficiency goiter	has a large mass in the front of the neck. The person sometimes has weakness and fatigue, constipation and weight gain.
Kwashiorkor	is very tired and irritable and has diarrhea.
Severe wasting	is extremely skinny and has no energy.
Speech problems	has difficulty speaking, and others find it difficult to understand.
Motor impairment, mild	has some difficulty in moving around but is able to walk without help.
Motor impairment, moderate	has some difficulty in moving around, and difficulty in lifting and holding objects, dressing and sitting upright, but is able to walk without help.
Motor impairment, severe	is unable to move around without help, and is not able to lift or hold objects, get dressed or sit upright.
Motor plus cognitive impairments, mild	has some difficulty in moving around but is able to walk without help. The person is slow in learning at school. As an adult, the person has some difficulty doing complex or unfamiliar tasks but otherwise functions independently.
Motor plus cognitive impairments, moderate	has some difficulty in moving around, holding objects, dressing and sitting upright, but can walk without help. The person has low intelligence and is slow in learning to speak and to do simple tasks.
Motor plus cognitive impairments, severe	cannot move around without help, and cannot lift or hold objects, get dressed or sit upright. The person also has very low intelligence, speaks few words, and needs constant supervision and help with all daily activities.
Rectovaginal fistula	has an abnormal opening between her vagina and rectum causing flatulence and feces to escape through the vagina. The person gets infections in her vagina, and has pain when urinating.
Vesicovaginal fistula	has an abnormal opening between the bladder and the vagina, which makes her unable to control urinating. The woman is anxious and depressed.

**Annex Table C Disability weights by health state used in WHO Global Health Estimates**

Health state	GHE2021	GBD 2021	GBD 2010	GBD 2004
<b>Infectious disease</b>				
Infectious disease: acute episode, mild	0.006	0.006	0.005	0.005
Infectious disease: acute episode, moderate	0.051	0.051	0.053	0.137
Infectious disease: acute episode, severe	0.133	0.133	0.210	0.615
Infectious disease: post-acute consequences (fatigue, emotional lability, insomnia)	0.219	0.219	0.254	
Diarrhoea: mild	0.074	0.074	0.061	
Diarrhoea: moderate	0.188	0.188	0.202	0.105
Diarrhoea: severe	0.247	0.247	0.281	
Epididymo-orchitis	0.128	0.128	0.097	0.167
Herpes zoster	0.058	0.058	0.061	
HIV: symptomatic, pre-AIDS	0.078	0.078	0.221	0.167
HIV/AIDS cases, receiving ARV treatment	0.274	0.274	0.053	0.135
AIDS cases, not receiving ARV treatment	0.582	0.582	0.547	0.505
Intestinal nematode infections: symptomatic	0.027	0.027	0.030	0.024
Lymphatic filariasis: symptomatic	0.109	0.109	0.110	0.106
Ear pain	0.013	0.013	0.018	0.023
Tuberculosis, not HIV infected	0.333	0.333	0.331	0.271
Tuberculosis, HIV infected	0.408	0.408	0.399	0.505
<b>Cancer</b>				
Cancer: diagnosis and primary therapy	0.288	0.288	0.294	0.095
Cancer: metastatic	0.451	0.451	0.484	0.750
Mastectomy	0.083	0.083	0.038	0.055
Stoma	0.139	0.139	0.086	0.075
Terminal phase: with medication (for cancers, end-stage kidney or liver disease)	0.540	0.540	0.508	0.810
Terminal phase: without medication (for cancers, end-stage kidney or liver disease)	0.569	0.569	0.519	0.810
<b>Cardiovascular diseases</b>				
Acute myocardial infarction: days 1-2	0.432	0.432	0.422	
Acute myocardial infarction: days 3-28	0.074	0.074	0.056	0.439
Angina pectoris: mild	0.033	0.033	0.037	
Angina pectoris: moderate	0.080	0.080	0.066	0.095
Angina pectoris: severe	0.167	0.167	0.167	0.227
Cardiac conduction disorders and cardiac dysrhythmias	0.224	0.224	0.145	0.193
Claudication	0.014	0.014	0.016	
Heart failure: mild	0.041	0.041	0.037	0.006
Heart failure: moderate	0.072	0.072	0.070	0.171
Heart failure: severe	0.179	0.179	0.186	0.323
Stroke: long-term consequences, mild	0.019	0.019	0.021	
Stroke: long-term consequences, moderate	0.070	0.070	0.076	
Stroke: long-term consequences, moderate plus cognition problems	0.316	0.316	0.312	0.266
Stroke: long-term consequences, severe	0.552	0.552	0.539	
Stroke: long-term consequences, severe plus cognition problems	0.588	0.588	0.567	0.920

Health state	GHE2021	GBD 2021	GBD 2010	GBD 2004
<b>Diabetes, digestive, and genitourinary disease</b>				
Diabetic neuropathy	0.133	0.133	0.099	0.072
Chronic kidney disease (stage IV)	0.104	0.104	0.105	0.104
End-stage renal disease: with kidney transplant	0.024	0.024	0.027	
End-stage renal disease: on dialysis	0.571	0.571	0.573	0.101
Decompensated cirrhosis of the liver	0.178	0.178	0.194	0.330
Gastric bleeding	0.325	0.325	0.323	
Crohn's disease or ulcerative colitis	0.231	0.231	0.225	0.042
Benign prostatic hypertrophy: symptomatic	0.067	0.067	0.070	0.038
Impotence	0.017	0.017	0.019	0.060
Stress incontinence	0.020	0.020		
Urinary incontinence	0.139	0.139	0.142	0.060
Infertility: primary	0.056	0.008	0.011	0.180
Infertility: secondary	0.026	0.005	0.006	0.180
<b>Chronic respiratory diseases</b>				
Asthma: controlled	0.015	0.015	0.009	
Asthma: partially controlled	0.036	0.036	0.027	0.043
Asthma: uncontrolled	0.133	0.133	0.132	
COPD and other chronic respiratory problems, mild	0.019	0.019	0.015	0.170
COPD and other chronic respiratory problems, moderate	0.225	0.225	0.192	0.170
COPD and other chronic respiratory problems, severe	0.408	0.408	0.383	0.530
<b>Neurological disorders</b>				
Dementia: mild	0.165	0.069	0.082	
Dementia: moderate	0.388	0.377	0.346	0.666
Dementia: severe	0.545	0.449	0.438	0.940
Headache: migraine	0.441	0.441	0.433	0.288
Migraine headache: moderate	0.267	0.267		
Headache: tension-type	0.037	0.037	0.040	
Headache, medication overuse	0.223	0.223		
Multiple sclerosis: mild	0.183	0.183	0.198	
Multiple sclerosis: moderate	0.463	0.463	0.445	0.411
Multiple sclerosis: severe	0.719	0.719	0.707	0.670
Epilepsy: treated, seizure free			0.072	0.065
Epilepsy: treated, with recent seizures			0.319	
Epilepsy: severe			0.657	
Epilepsy: untreated			0.420	0.150
Epilepsy, less severe (seizures < once per month)	0.263	0.263		
Epilepsy, severe (seizures >= once per month)	0.552	0.552		
Parkinson's disease: mild	0.010	0.010	0.011	
Parkinson's disease: moderate	0.267	0.267	0.263	0.316
Parkinson's disease: severe	0.575	0.575	0.549	0.392
<b>Mental, behavioural, and substance use disorders</b>				
Alcohol problem use	0.115			0.134
Alcohol use disorder, very mild	0.123	0.123		

Health state	GHE2021	GBD 2021	GBD 2010	GBD 2004
Alcohol use disorder: mild	0.235	0.235	0.259	0.134
Alcohol use disorder: moderate	0.373	0.373	0.388	0.180
Alcohol use disorder: severe	0.570	0.570	0.549	
Fetal alcohol syndrome: mild	0.016	0.016	0.017	
Fetal alcohol syndrome: moderate	0.056	0.056	0.057	
Fetal alcohol syndrome: severe	0.179	0.179	0.177	
Cannabis dependence	0.266	0.266	0.329	0.252
Cannabis dependence, mild	0.039	0.039		
Amphetamine dependence	0.486	0.486	0.353	0.252
Amphetamine dependence, mild	0.079	0.079		
Cocaine dependence	0.479	0.479	0.376	0.252
Cocaine dependence, mild	0.116	0.116		
Heroin and other opioid dependence	0.697	0.697	0.641	0.252
Heroin and other opioid dependence, mild	0.335	0.335		
Anxiety disorders: mild	0.030	0.030	0.030	0.091
Anxiety disorders: moderate	0.133	0.133	0.149	0.173
Anxiety disorders: severe	0.523	0.523	0.523	0.560
Major depressive disorder: mild episode	0.145	0.145	0.159	0.140
Major depressive disorder: moderate episode	0.396	0.396	0.406	0.350
Major depressive disorder: severe episode	0.658	0.658	0.655	0.760
Bipolar disorder: manic episode	0.492	0.492	0.480	0.400
Bipolar disorder: residual state	0.032	0.032	0.035	0.140
Schizophrenia: acute state	0.778	0.778	0.756	0.627
Schizophrenia: residual state	0.588	0.588	0.576	0.351
Anorexia nervosa	0.224	0.224	0.223	0.280
Bulimia nervosa	0.223	0.223	0.223	0.280
Attention-deficit hyperactivity disorder	0.045	0.045	0.049	0.020
Conduct disorder	0.241	0.241	0.236	0.150
Asperger's syndrome	0.104	0.104	0.110	
Autism	0.262	0.262	0.259	0.550
Borderline intellectual functioning	0.011	0.011	0.0034	
Intellectual disability / mental retardation, mild	0.127	0.043	0.031	0.290
Intellectual disability / mental retardation, moderate	0.293	0.100	0.080	0.430
Intellectual disability / mental retardation, severe	0.383	0.160	0.126	0.820
Intellectual disability / mental retardation, profound	0.444	0.200	0.157	0.760
Hearing and vision loss				
Hearing loss: mild	0.010	0.010	0.005	0.040
Hearing loss: moderate	0.050	0.027	0.023	0.120
Hearing loss: severe	0.167	0.158	0.031	0.333
Hearing loss: profound	0.281	0.204	0.032	0.333
Hearing loss: complete	0.281	0.215	0.033	
Hearing loss: mild, with ringing	0.038	0.021	0.038	
Hearing loss: moderate, with ringing	0.095	0.074	0.058	
Hearing loss: severe, with ringing	0.220	0.261	0.065	

Health state	GHE2021	GBD 2021	GBD 2010	GBD 2004
Hearing loss: profound, with ringing	0.320	0.277	0.092	
Hearing loss: complete, with ringing	0.327	0.327	0.088	
Distance vision, monocular	0.017	0.017		
Distance vision: mild impairment	0.005	0.005	0.004	
Distance vision: moderate impairment	0.089	0.089	0.033	0.170
Distance vision: severe impairment	0.314	0.314	0.191	0.430
Distance vision blindness	0.338	0.338	0.195	0.600
<b>Musculoskeletal disorders</b>	<b>0.022</b>	<b>0.022</b>		
Back pain, most severe, without leg pain	0.372	0.372	0.269	0.061
Back pain, most severe, with leg pain	0.384	0.384	0.322	0.061
Back pain, severe, without leg pain	0.272	0.272	0.366	
Back pain, severe, with leg pain	0.325	0.325	0.374	0.125
Low back pain, moderate	0.054	0.054		
Low back pain, mild	0.020	0.020		
Neck pain: acute, mild			0.040	
Neck pain: acute, severe			0.221	
Neck pain: chronic, mild			0.101	
Neck pain: chronic, severe			0.286	
Neck pain, mild	0.053	0.053		
Neck pain, moderate	0.114	0.114		
Neck pain, severe	0.229	0.229		
Neck pain, most severe	0.304	0.304		
Musculoskeletal problems, lower limbs, mild	0.023	0.023	0.023	
Musculoskeletal problems, lower limbs, moderate	0.079	0.079	0.079	0.108
Musculoskeletal problems, lower limbs, severe	0.165	0.165	0.171	0.156
Musculoskeletal problems, upper limbs, mild	0.028	0.028	0.024	
Musculoskeletal problems, upper limbs, moderate	0.117	0.117	0.114	0.174
Musculoskeletal problems, generalized, moderate	0.317	0.317	0.292	0.233
Musculoskeletal problems, generalized, severe	0.581	0.581	0.606	
Gout: acute	0.295	0.295	0.293	0.132
<b>Injuries</b>				
Amputation of finger(s), excluding thumb: long term, with treatment	0.005	0.005	0.030	0.102
Amputation of thumb: long term	0.011	0.011	0.013	0.165
Amputation of one arm: long term, with or without treatment	0.118	0.118	0.130	0.102
Amputation of both arms: long term, with treatment	0.123	0.123	0.044	
Amputation of both arms: long term, without treatment	0.383	0.383	0.359	
Amputation of toe	0.006	0.006	0.008	0.064
Amputation of one leg: long term, with treatment	0.039	0.039	0.021	0.300
Amputation of one leg: long term, without treatment	0.173	0.173	0.164	0.300
Amputation of both legs: long term, with treatment	0.088	0.088	0.051	
Amputation of both legs: long term, without treatment	0.443	0.443	0.494	
Burns of <20% total surface area without lower airway burns: short term, with or without treatment	0.141	0.141	0.096	0.157
Burns of <20% total surface area or <10% total surface area if head or neck, or hands or wrist involved: long term, with or without treatment	0.016	0.016	0.018	0.002

Health state	GHE2021	GBD 2021	GBD 2010	GBD 2004
Burns of ≥20% total surface area: short term, with or without treatment	0.314	0.314	0.333	0.455
Burns of ≥20% total surface area or ≥10% total surface area if head or neck, or hands or wrist involved: long term, with treatment	0.135	0.135	0.127	0.255
Burns of ≥20% total surface area or ≥10% total surface area if head or neck, or hands or wrist involved: long term, without treatment	0.455	0.455	0.438	0.255
Lower airway burns: with or without treatment	0.376	0.376	0.373	
Crush injury: short or long term, with or without treatment	0.132	0.132	0.145	0.218
Dislocation of hip: long term, with or without treatment	0.016	0.016	0.017	
Dislocation of knee: long term, with or without treatment	0.113	0.113	0.129	0.074
Dislocation of shoulder: long term, with or without treatment	0.062	0.062	0.080	0.074
Other injuries of muscle and tendon (includes sprains, strains, and dislocations other than shoulder, knee, or hip)	0.008	0.008	0.009	
Drowning and non-fatal submersion: short or long term, with or without treatment	0.247	0.247	0.288	
Fracture of clavicle, scapula, or humerus: short or long term, with or without treatment	0.035	0.035	0.053	0.153
Fracture of face bone: short or long term, with or without treatment	0.067	0.067	0.173	0.223
Fracture of foot bones: short term, with or without treatment	0.026	0.026	0.033	0.077
Fracture of foot bones: long term, without treatment	0.026	0.026	0.033	
Fracture of hand: short term, with or without treatment	0.010	0.010	0.025	0.100
Fracture of hand: long term, without treatment	0.014	0.014	0.016	
Fracture of neck of femur: short term, with or without treatment	0.258	0.258	0.308	0.372
Fracture of neck of femur: long term, with treatment	0.058	0.058	0.072	0.272
Fracture of neck of femur: long term, without treatment	0.402	0.402	0.388	0.272
Fracture other than neck of femur: short term, with or without treatment	0.111	0.111	0.192	
Fracture other than neck of femur: long term, without treatment	0.042	0.042	0.053	
Fracture of patella, tibia or fibula, or ankle: short term, with or without treatment	0.050	0.050	0.087	0.271
Fracture of patella, tibia or fibula, or ankle: long term, with or without treatment	0.055	0.055	0.070	
Fracture of pelvis: short term	0.279	0.279	0.390	0.247
Fracture of pelvis: long term	0.182	0.182	0.194	
Fracture of radius or ulna: short term, with or without treatment	0.028	0.028	0.065	0.180
Fracture of radius or ulna: long term, without treatment	0.043	0.043	0.050	
Fracture of skull: short or long term, with or without treatment	0.071	0.071	0.073	0.431
Fracture of sternum or fracture of one or two ribs: short term, with or without treatment	0.103	0.103	0.150	0.199
Fracture of vertebral column: short or long term, with or without treatment	0.111	0.111	0.132	0.266
Fractures: treated, long term	0.005	0.005	0.003	
Injured nerves: short term	0.100	0.100	0.065	0.071
Injured nerves: long term	0.113	0.113	0.136	0.071
Injury to eyes: short term	0.054	0.054	0.079	0.108
Severe traumatic brain injury: short term, with or without treatment	0.110	0.110	0.235	0.359
Concussion	0.214	0.214		
Traumatic brain injury: long-term consequences, minor, with or without treatment	0.094	0.094	0.106	0.370
Traumatic brain injury: long-term consequences, moderate, with or without treatment	0.231	0.231	0.224	0.396
Traumatic brain injury: long-term consequences, severe, with or without treatment	0.637	0.637	0.625	0.730
Open wound: short term, with or without treatment	0.006	0.006	0.005	0.105
Poisoning: short term, with or without treatment	0.163	0.163	0.171	0.608

Health state	GHE2021	GBD 2021	GBD 2010	GBD 2004
Severe chest injury: long term, with or without treatment	0.047	0.047	0.056	
Severe chest injury: short term, with or without treatment	0.369	0.369	0.352	
Spinal cord lesion below neck: treated	0.296	0.296	0.047	0.570
Spinal cord lesion below neck: untreated	0.623	0.623	0.440	0.672
Spinal cord lesion at neck: treated	0.589	0.589	0.369	
Spinal cord lesion at neck: untreated	0.732	0.732	0.673	0.725
Other				
Abdominopelvic problem: mild	0.011	0.011	0.012	0.000
Abdominopelvic problem: moderate	0.114	0.114	0.123	0.122
Abdominopelvic problem: severe	0.324	0.324	0.326	0.463
Anaemia: mild	0.004	0.004	0.005	0.000
Anaemia: moderate	0.052	0.052	0.058	0.011
Anaemia: severe	0.149	0.149	0.164	0.090
Thrombocytopenic purpura	0.159	0.159		
Periodontitis	0.007	0.007	0.008	0.001
Dental caries:symptomatic	0.010	0.010	0.012	0.081
Severe toothloss	0.067	0.067	0.072	0.061
Disfigurement: level 1	0.011	0.011	0.013	0.023
Disfigurement: level 2	0.067	0.067	0.072	0.056
Disfigurement: level 3	0.405	0.405	0.398	0.074
Disfigurement: level 1 with itch or pain	0.027	0.027	0.029	
Disfigurement: level 2, with itch or pain	0.188	0.188	0.187	0.068
Disfigurement: level 3, with itch or pain	0.576	0.576	0.562	
Generic uncomplicated disease: worry and daily medication	0.049	0.049	0.031	0.033
Generic uncomplicated disease: anxiety about diagnosis	0.012	0.012	0.054	
Hyperthyroidism	0.145	0.145		
Hypothyroidism	0.019	0.019		
Iodine-deficiency goitre	0.199	0.199	0.200	0.025
Kwashiorkor	0.051	0.051	0.055	
Severe wasting	0.128	0.128	0.127	0.053
Speech problems	0.051	0.051	0.054	
Motor impairment: mild	0.010	0.010	0.012	0.010
Motor impairment: moderate	0.061	0.061	0.076	0.381
Motor impairment: severe	0.402	0.402	0.377	
Motor plus cognitive impairments: mild	0.031	0.031	0.054	0.024
Motor plus cognitive impairments: moderate	0.203	0.203	0.221	0.283
Motor plus cognitive impairments: severe	0.542	0.542	0.425	0.804
Rectovaginal fistula	0.501	0.501	0.492	0.430
Vesicovaginal fistula	0.342	0.342	0.338	